conferenceseries.com
1718th Conference

June 2018 | Volume 9
ISSN: 2157-7412
Journal of Genetic Syndromes & Gene Therapy

Proceedings of

4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland



Scientific Program

Rare Diseases Congress-2018

Day 1 June 11, 2018

09:00-09:30 Registrations

Manor Suite

conferenceseries.com 09:30-09:50 **Opening Ceremony**

Keynote Forum

09:50-10:00	Introduction
10:00-10:40	Title:Serotonergic targets in the treatment of pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH) **Laxminarayan Bhat, Reviva Pharmaceuticals Inc, USA**
	Networking & Refreshment Break: 10:40-11:00 @ Foyer
11:00-11:40	Title: Surgical treatment of early onset scoliosis associated with rare disease **Gianluca Colella,** Rizzoli Orthopaedic Institute, Italy
11:40-12:20	Title: Clinical course and outcomes of critically ill patients with middle-east respiratory syndrome coronavirus infection **Abdulaziz Aldawood,** King Saud Bin Abdulaziz University, Saudi Arabia
Sessions: Rare Genetic Diseases | Pediatric Rare Diseases | Rare Hereditary Diseases | Diagnosis and Treatment for Rare Diseases | Clinical case studies on Rare Diseases	
Session Chair: **Karren Williams,** Akcea Therapeutics, USA Session Chair: **Alan Gilstrap,** Akcea Therapeutics, USA	
	Session Introduction
12:20-12:50	Title: Rare diagnosis in disorders/differences of sex development **Yolande van Bever, Erasmus Medical Centre, The Netherlands**
12:50-13:20	Title: Evaluating the impact of peer support and connection on the quality of life of patients with familial Chylomicronemia Syndrome **Alan Gilstrap, Akcea Therapeutics, USA**
	Lunch Break: 13:20- 14:20 @ Peacock Restaurant
	Workshop
14:20- 15:00	Title: Pulmonary arterial hypertension and pulmonary fibrosis: Treatments, unmet needs, and future directions **Laxminarayan Bhat, Reviva Pharmaceuticals, Inc, USA**
	Session
15:00-15:30	Title: Synthetic messenger RNA-based therapeutic strategy for treatment of alpha-1-antitrypsin deficiency **Tatjana Michel, University Hospital Tuebingen, Germany**
	Workshop
15:30-16:00	Title: Surgical treatment of scoliosis in rare diseases: Arthogryposis **Gianluca Colella, Rizzoli Orthopaedic Institute, Italy**
	Networking & Refreshment Break: 16:00-16:20 @ Foyer
	Session
16:20-16:50	Title: Rare diseases in Kuwait: The experience of Genatak Center for Genomic Medicine **Fahd Al Mulla, Kuwait University, Kuwait**
	Panel Discussion

Day 2 June 12, 2018

Manor Suite

Sessions: Current Rare Diseases Research | Orphan Drugs Market Research | Rare Diseases of Sexual Health | Scope of Orphan Drugs | Rare Diseases in Neurology

Session Chair: Karren Williams, Akcea Therapeutics, USA

Session Chair: Alan Gilstrap, Akcea Therapeutics, USA

Session Introduction

10:00-10:30	**Title: Results of the investigation of findings and observations captured in burden of illness survey in FCS patients (in-focus) study: European respondents** **Karren Williams,** Akcea Therapeutics, USA

Networking & Refreshment Break: 10:30- 10:50 @ Foyer

10:50- 11:20	**Title: Hepatitis c virus testing and treatment among persons receiving buprenorphine in an office -based program for opioid use disorders in Nigeria** **Samuel Ayoola Abati,** lagos university, Nigeria

Workshop

11:20- 13:00	**Title: Synthetic messenger RNA (mRNA) as a therapeutic tool** **Tatjana Michel,** University Hospital Tuebingen, Germany

Lunch Break 13:00 - 14:00 @ Peacock Restaurant

14:00- 14:30	**Title: Rare diseases in west Africa** **Ndiaye Mady,** Faculty of Medicine of Thiès, Nigeria

Poster Presentations

Panel Discussion

Awards Ceremony



List of Open Access Journals

Agri, Food & Aqua

Advances in Crop Science and Technology	2329-8863
Advances in Dairy Research	2329-888X
Agrotechnology	2168-9881
Aquaculture Research & Development	2155-9546
Arabidopsis C. Elegans and Zebrafish	-
Biofertilizers & Biopesticides	2155-6202
Crop Research	2454-1761
Experimental Food Chemistry	-
Fisheries & Livestock Production	2332-2608
Fisheries and Aquaculture Journal	2150-3508
Fisheriessciences	1307-234X
Food & Industrial Microbiology	-
Food & Nutritional Disorders	2324-9323
Food Processing & Technology	2157-7110
Food: Microbiology, Safety & Hygiene	-
Forest Research	2168-9776
Horticulture	2376-0354
International Biodiversity, Bioprospecting and Development	2376-0214
Marine Science: Research & Development	2155-9910
Medicinal & Aromatic Plants	2167-0412
Nutrition & Food Sciences	2155-9600
Plant Pathology & Microbiology	2157-7471
Poultry, Fisheries & Wildlife Sciences	2375-446X
Probiotics & Health	2329-8901
Research & Reviews: Journal of Agriculture and Allied Sciences	2347-226X
Research & Reviews: Journal of Food and Dairy Technology	2321-6204
Rice Research	2375-4338
Traditional Medicine and Clinical Naturopathy (Homeopathy & Ayurvedic Medicine-2167-1206)	-

Business & Management

Accounting & Marketing	2168-9601
Arabian Journal of Business and Management Review	2223-5833
Business & Financial Affairs	2167-0234
Business & Hotel Management	2324-9129
Business and Economics Journal	2151-6219
Defense Studies & Resource Management	2324-9314
Entrepreneurship & Organization Management	2169-026X
Global Economics	2375-4389
Hotel & Business Management	2169-0286
International Journal of Accounting Research	-
International Journal of Economics and Management Science	2162-6359
Internet Banking & Commerce	1204-5357
Review of Public Administration and Management	2315-7844
Stock & Forex Trading	2168-9458
Tourism & Hospitality	2167-0269

Chemical Engineering

Advanced Chemical Engineering	2090-4568
Bioprocessing & Biotechniques	2155-9821
Chemical Engineering & Process Technology	2157-7048
Thermodynamics & Catalysis	2157-7544

Chemistry

Analytical & Bioanalytical Techniques	2155-9872
Analytical & Electrochemical Insights	-
Bioenergetics: Open Access	2167-7662
Chemical Informatics	-
Chemical Sciences Journal	2150-3494
Chromatography & Separation Techniques	2157-7064
Clinical & Medical Biochemistry: Open Access	-
Clinical Chemistry: Open Access	-
Environmental & Analytical Toxicology	2161-0525
Environmental Analytical Chemistry	-
Glycobiology	2168-958X
Herbal Medicine: Open Access	-
Immuno Chemistry: Open Access	-
Industrial Chemistry: Open Access	-
International Journal of Applied Biology and Pharmaceutical Technology	0976-4550
International Journal of Drug Development & Research	0975-9344
Mass Spectrometry: Open Access	-
Medicinal Chemistry	2161-0444
Modern Chemistry & Applications	2329-6798
Natural Products Chemistry & Research Journal	2329-6836
Neuro Chemistry: Open Access	-
Organic & Inorganic Chemistry	-
Organic Chemistry: Current Research	2161-0401
Pharmaceutical Analytical Chemistry: Open Access	-
Physical Chemistry & Biophysics	2161-0398
RROIJ: Medicinal Chemistry	-
Structural Chemsitry & Crystallography Communication	-
Trends in Green Chemistry	-
Vitamins & Minerals	2376-1318

Clinical

Ageing Science	2329-8847
Ancient Diseases & Preventive Remedies	2329-8731
Anesthesia & Clinical Research	2155-6148
Annals of Clinical and Laboratory Research	2386-5180
Arrhythmia: Open Access	-
Atherosclerosis: Open Access	-
Cell Biology: Research & Therapy	2324-9293
Cellular & Molecular Pathology	-
Clinical & Experimental Cardiology	2155-9880
Clinical & Experimental Dermatology Research	2155-9554
Clinical & Experimental Nephrology	-
Clinical & Experimental Oncology	2324-9110
Clinical & Experimental Ophthalmology	2155-9570
Clinical & Experimental Orthopaedics	-
Clinical & Experimental Pathology	2161-0681
Clinical & Molecular Endocrinology	-
Clinical and Experimental Psychology	-
Clinical and Experimental Transplantation	-
Clinical Case Reports	2165-7920
Clinical Depression	-
Clinical Dermatology Research Journal	-
Clinical Diabetes & Practice	-
Clinical Nutrition & Dietetics	-
Clinical Oncology and Practice	-
Clinical Pediatrics	-
Clinical Pediatrics & Dermatology	-
Clinical Psychiatry	-
Clinical Research & Bioethics	2155-9627
Clinical Research On Foot & Ankle	2329-910X
Clinical Respiratory: Open Access	-
Clinical Toxicology	2161-0495
Clinical Trials	2167-0870
Clinics in Mother and Child Health	2090-7214
Cosmetology & Orofacial Surgery	-
Cosmetology & Trichology	-
Dermatitis	-
Diabetes Case Reports	-
Dialysis and Clinical Practice	-
Drug Intoxication & Detoxification : Novel Approaches	2327-4557
Dual Diagnosis: Open Access	-
Eye & Cataract Refractive Surgery	-
Forensic Toxicology & Pharmacology	2325-9841
Glaucoma: Open Access	-
HIV & Retro Virus	-
Immunooncology	-
Insights in Pediatric Cardiology	-

Intensive and Critical Care	-
International Journal of Anesthesiology & Pain Medicine	-
International Journal of Cardiovascular Research	2324-8602
International Journal of Digestive Diseases	-
International Journal of Ophthalmic Pathology	2324-8599
Interventional Cardiology: Open Access	-
JBR Journal of Clinical Diagnosis and Research	2376-0311
Optometry: Open Access	-
Phonetics & Audiology	-
Speech Pathology & Therapy	-
Stem Cell Research & Therapy	2157-7633
Toxicology: Open Access	-
Vasculitis	-

Earth & Environmental Sciences

Advances in Recycling	-
Astrobiology & Outreach	2332-2519
Biodiversity & Endangered Species	2332-2543
Biodiversity Management & Forestry	2327-4417
Bioremediation & Biodegradation	2155-6199
Biosafety	2167-0331
Climatology & Weather Forecasting	2332-2594
Coastal Zone Management	-
Earth Science & Climatic Change	2157-7617
Ecosystem & Ecography	2157-7625
Entomology, Ornithology & Herpetology	2161-0983
Expert Opinion On Environmental Biology	2325-9655
Fundamentals of Renewable Energy and Applications	2090-4541
Geography & Natural Disasters	2167-0587
Geoinformatics & Geostatistics: An Overview	2327-4581
Geology & Geosciences	2329-6577
Geophysics & Remote Sensing	2169-0049
Hydrogeology & Hydrologic Engineering	2325-9647
Hydrology: Current Research	2157-7587
Industrial Pollution Control	-
Innovative Energy Policies	2090-5009
International Journal of Evolution	2324-8548
International Journal of Waste Resources	2252-5211
Marine Biology & Oceanography	2324-8661
Oceanography: Open Access	2332-2632
Oil & Gas: Open Access	-
Petroleum & Environmental Engineering	2157-7463
Plant Physiology & Pathology	2329-955X
Pollution Effects & Control	2375-4397
Research & Reviews: Journal of Ecology and Environmental Sciences	-

EEE

Electrical & Electronic Systems	2332-0796
Electrical Engineering & Electronic Technology	2325-9833

Engineering

Advances in Automobile Engineering	2167-7670
Advances in Robotics & Automation	2168-9695
Aeronautics & Aerospace Engineering	2168-9792
Applied Bioinformatics & Computational Biology	2329-9533
Applied Mechanical Engineering	2168-9873
Architectural Engineering Technology	2168-9717
Automatic Control of Physiological State and Function	2090-5092
Biochips & Tissue Chips	2153-0777
Bioengineering & Biomedical Science	2155-9538
Biomusical Engineering	2090-2719
Biosensors & Bioelectronics	2155-6210
Biosensors Journal	2090-4967
Civil & Environmental Engineering	2165-784X
Computer Engineering & Information Technology	2324-9307
Computer Engineering and Information Technology	2324-9307
Defense Management	2167-0374
Fashion Technology & Textile Engineering	2329-9568
Global Journal of Technology and Optimization	2229-8711
Global Research in Computer Science	2229-371X
Industrial Engineering & Management	2169-0316
Information Technology & Software Engineering	2165-7866
International Journal of Advanced Research in Electrical, Electronics and Instrumentation Engineering	2278-8875
International Journal of Advancements in Technology	0976-4860
International Journal of Biomedical Data Mining	2090-4924
International Journal of Innovative Research in Computer and Communication Engineering	2278-1021
International Journal of Innovative Research in Science, Engineering and Technology	2319-8753
International Journal of Sensor Networks and Data Communications	2090-4886
International Journal of Swarm Intelligence and Evolutionary Computation	2090-4908
Irrigation & Drainage Systems Engineering	2168-9768
Lasers, Optics & Photonics	-
Lovotics	2090-9888
Membrane Science & Technology	2155-9589
Molecular Imaging & Dynamics	2155-9937
Nuclear Energy Science & Power Generation Technology	2325-9809
Research & Reviews: Journal of Engineering and Technology	2319-9873
Steel Structures & Construction	-
Telecommunications System & Management	2167-0919
Textile Science & Engineering	2165-8064

General Science

Computer Science & Systems Biology Journal	0974-7230
Ergonomics	2165-7556
Research and Development	-
International Journal of Advance Innovations, Thoughts & Ideas	2277-1891
Metrology	-
Research & Reviews: Journal of Botanical Sciences	2320-0189
Research & Reviews: Journal of Chemistry	2319-9849
Tomography	-

Genetics & Molecular Biology

Advanced Techniques in Biology & Medicine	2379-1764
Advancements in Genetic Engineering	2169-0111
Advances in Molecular Diagnostics	-
Biochemistry & Analytical Biochemistry	2161-1009
Biochemistry & Molecular Biology Journal	-
Biochemistry & Physiology	2329-9029
Biological Systems	2329-6577
Biotechnology & Biomaterials	2155-952X
Bipolar Disorder: Open Access	-
Cell & Developmental Biology	2168-9296
Cell Science & Therapy	2157-7013
Cell Signaling	-
Cellular & Molecular Medicine: Open Access	-
Chemical Biology & Therapeutics	-
Clinical Epigenetics	-
Cloning & Transgenesis	2168-9849
Current Synthetic and Systems Biology	2332-0737
Cytology & Histology	2157-7099
Down Syndrome & Chromosome Abnormalities	-
Electronic Journal of Biology	-
Enzyme Engineering	2329-6674
Fertilization: in Vitro	2375-4508
Fungal Genomics & Biology	2165-8056
Gene Technology	2329-6682
Genetic Syndromes & Gene Therapy	2157-7412
Hereditary Genetics: Current Research	2161-1041
Human Genetics & Embryology	2161-0436
Insights in Cell Science	-
Insights in Stem Cells	-
International Journal of Genomic Medicine	2332-0672
Metabolomics: Open Access	2153-0769
Metabonomics & Metabolites	2325-9736
Microbial & Biochemical Technology	1948-5948
Microbial Methods & Assays Open Access	-
Molecular and Genetic Medicine	1747-0862
Molecular Biology	2168-9547
Molecular Biomarkers & Diagnosis	2155-9929
Molecular Cloning & Genetic Recombination	2325-9787
Nanomedicine & Biotherapeutic Discovery	2155-983X
Next Generation: Sequencing & Applications	-
Phylogenetics & Evolutionary Biology	2329-9002

Physiobiochemical Metabolism	2324-8793
Plant Biochemistry & Physiology	2329-9029
Proteomics & Enzymology	-
Single Cell Biology	2168-9431
Tissue Science & Engineering	2157-7552
Transcriptomics: Open Access	2329-8936
Translational Biomedicine	2172-0479

Health Care

Diversity and Equality and Health and Care	2049-5471
Health Care: Current Reviews	2375-4273
Health Science Journal	1791-809X
Pregnancy & Child Health	2376-127X
Primary Health Care	2167-1079
Quality in Primary Care	1479-1072
Tropical Diseases & Public Health	2329-891X
Women'S Health, Issues & Care	2325-9795

Immunology

Advances in Antibiotics & Antibodies	-
Allergy & Therapy	2155-6121
Autoimmune Diseases: Open Access	-
Clinical & Cellular Immunology	2155-9899
Cytokine Biology	-
Immunobiology	-
Immunogenetics: Open Access	-
Immunome Research	1745-7580
Immunotherapy: Open Access	-
Infectious Diseases & Immunological Techniques	2325-9752
Inflammatory Bowel Diseases & Disorders	-
Innate Immunity & Immunological Disorders	-
Interdisciplinary Journal of Microinflammation	-
Lupus: Open Access	-
Molecular Immunology	-
Osteoarthritis	-
Reproductive Immunology	-
Rheumatology: Current Research	2161-1149
Sarcoidosis	-
Vaccines & Vaccination	2157-7560

Informatics

Data Mining in Genomics & Proteomics	2153-0602
Glycomics and Lipidomics	2153-0637
Health & Medical Informatics	2157-7420
Proteomics & Bioinformatics	0974-276X
Theoretical and Computational Science	2376-130X

Materials Science

Bioceramics Developments and Applications	2090-5025
Material Sciences & Engineering	2169-0022
Nano Research & Applications	-
Nanomaterials & Molecular Nanotechnology	2324-8777
Nanomedicine & Nanotechnology	2157-7439
Plastic & Polymer Sciences	-
Powder Metallurgy & Mining	2168-9806
Research & Reviews: Journal of Material Sciences	2321-6212

Mathematics

Applied & Computational Mathematics	2168-9679
Biometrics & Biostatistics	2155-6180
Generalized Lie Theory and Applications	1736-4337
Physical Mathematics	2090-0902
Research & Reviews: Journal of Statistics and Mathematical Sciences	-

Medical

Abnormal and Behavioural Psychology	-
Acta Psychopathologica	-
Acta Rheumatologica	-
Addictive Behaviors , Therapy & Rehabilitation	2324-9005
Adenocarcinoma	-
Advances in Cancer Prevention	-
Advances in Genetic Engineering & Biotechnology	-
Advances in Weight Loss Management & Medical Devices	-
Aerobics & Fitness	-
Aesthetic & Reconstructive Surgery	-
Aids & Clinical Research	2155-6113
Air and Water Borne Diseases	2167-7719
Alternative & Integrative Medicine	2327-5162
Analgesia & Resuscitation : Current Research	2324-903X
Anaplastology	2161-1173
Anatomy & Physiology: Current Research	2161-0940
Andrology & Gynecology: Current Research	2327-4360
Andrology	2167-0250
Angiology: Open Access	2329-9495
Annals of Behavioural Science	-
Applied and Rehabilitation Psychology: Open Access	-
Archives in Cancer Research	2254-6081
Archives of Medicine	1989-5216
Archives of Surgical Oncology	-
Archivos De Medicina	1698-9465
Arthritis	2167-7921
Asthma and Bronchitis	-
Athletic Enhancement	2324-9080
Autacoids & Hormones	2161-0479
Biology and Medicine	0974-8369
Biomedical Engineering & Medical Devices	-
Biomedical Sciences	2254-609X
Bioterrorism & Biodefense	2157-2526
Blood	-
Blood & Lymph	2165-7831
Blood Disorders & Transfusion	2155-9864
Blood Pressure: Open Access	-
Bone Marrow Research	2329-8820
Bone Reports & Recommendations	-
Brain Tumors	-
Breast Cancer: Current Research	-
Cancer Biomarkers	-
Cancer Clinical Trials	-
Cancer Diagnosis	-
Cancer Medicine & Anticancer Drugs	-
Cancer Science & Therapy	1948-5956
Cancer Surgery	-
Carcinogenesis & Mutagenesis	2157-2518
Cardiovascular Diseases & Diagnosis	2329-9517
Cardiovascular Pathology: Open Access	-
Celiac Disease: Open Access	-
Cervical Cancer: Open Access	-
Chemotherapy	2167-7700
Chest Diseases	-
Childhood & Developmental Disorders	-
Childhood Obesity	-
Chronic Obstructive Pulmonary Disease: Open Access	-
Colorectal Cancer: Open Access	-
Communication Disorders, Deaf Studies & Hearing Aids	2375-4427
Community Medicine & Health Education	2161-0711
Complex Diseases and Treatment	-
Contraceptive Studies	-
Critical Care Obstetrics & Gynecology	-
Current Trends in Gynecologic Oncology	-
Dental Health: Current Research	-
Dental Implants and Dentures: Open Access	-
Dentistry	2161-1122
Depression and Anxiety	2167-1044
Dermatology Case Reports	-
Diabetes & Metabolism	2155-6156
Diabetes Medication and Care	-
Diabetic Complications and Medicine	-
Drug Abuse	-
Emergency Medicine	2165-7548
Endocrinology & Diabetes Research	-
Endocrinology & Metabolic Syndrome	2161-1017
Epidemiology: Open Access	2161-1165
Evidence based Medicine and Practice	-
Family Medicine & Medical Science Research	2327-4972
Forensic Biomechanics	2090-2697
Forensic Medicine	-

Forensic Nursing: Open Access	-
Forensic Odontology	-
Forensic Psychology	-
Forensic Research	2157-7145
Gastrointestinal & Digestive System	2161-069x
Gastrointestinal Cancer and Stromal Tumors	-
General Medicine	2327-5146
General Practice	2329-9126
Genetic Disorders & Genetic Reports	2327-5790
Genital System & Disorders	2325-9728
Geriatric Psychiatry	-
Gerontology & Geriatric Research	2167-7182
Gynecology & Obstetrics	2161-0932
Gynecology & Obstetrics- Case Report	-
Haematology & Thromboembolic Diseases	2329-8790
Hair: Therapy & Transplantation	2167-0951
Head and Neck Cancer Research	-
Health & Medical Economics	-
Health Care Communications	-
Health Economics & Outcome Research: Open Access	-
Health Education Research & Development (Biosafety & Health Education: Open Access-2332-0893)	-
Health Systems and Policy Research	2254-9137
Heart Transplant and Surgery	-
Heavy Metal & Chelation Therapy	-
Hepatology and Gastrointestinal Disorders	-
Hospital & Medical Management	-
Hypertension- Open Access	2167-1095
Hypo & Hyperglycemia	2327-4700
Imaging and Interventional Radiology	-
Medical Implants & Surgery	-
Informatics and Data Mining	-
Insights in Biomedicine	-
Insights in Medical Physics	-
Integrative Oncology	2329-6771
Internal Medicine	2165-8048
International Journal of Clinical & Medical Imaging	2376-0249
International Journal of Collaborative Research on Internal Medicine & Public Health	-
International Journal of Emergency Mental Health and Human Resilience	1522-4821
International Journal of Mental Health & Psychiatry	2327-4654
International Journal of Pediatric Neurosciences	-
International Journal of Physical Medicine & Rehabilitation	2329-9096
International Journal of Public Health and Safety	-
International Journal of School and Cognitive Psychology	-
Interventional Pediatrics	-
Invasive Cardiology Future Medicine	-
JBR Journal of Interdisciplinary Medicine and Dental Sciences	2376-032X
Kidney	-
Kidney Transplant	-
La Prensa Medica	0032-745X
Laser Surgery and Therapy	-
Leukemia	2329-6917
Liposuction	-
Liver	2167-0889
Liver: Disease & Transplantation	2325-9612
Lung Cancer Diagnosis & Treatment	-
Lung Diseases & Treatment	-
Malaria Control & Elimination	2090-2778
Maternal and Pediatric Nutrition	-
Medical & Surgical Pathology	-
Medical & Surgical Urology	2168-9857
Medical and Clinical Reviews	-
Medical Case Reports	-
Medical Diagnostic Methods	2168-9784
Medical Toxicology and Clinical Forensic Medicine	-
Melanoma and Skin Diseases	-
Mental Health in Family Medicine	2327-4972
Mental Illness and Treatment	-
Metabolic Syndrome	2167-0943
Molecular & Medical Histology	-
Molecular Medicine & Therapeutics	2324-8769
Neonatal Biology	2167-0897
Neonatal Studies	-
Neonatal Medicine	-
Neoplasm	-
Nephrology & Therapeutics	2161-0959
Neurobiotechnology	-
Neuroinfectious Diseases	2314-7326
Neurooncology: Open Access	-
Neurosurgery & Cardiac Surgery	-
Novel Physiotherapies	2165-7025
Nuclear Medicine & Radiation Therapy	2155-9619
Nutritional Disorders & Therapy	2161-0509
Obesity & Eating Disorders	-
Obesity & Weight Loss Therapy	2165-7904
Occupational Medicine Health Affairs	2329-6879
Omics Journal of Radiology	2167-7964
Oncology & Cancer Case Reports	-
Oncology Translational Research	-
Oral Health and Dental Management	2247-2452
Oral Health Case Reports	-
Oral Hygiene & Health	2332-0702
Orthodontics & Endodontics	-
Orthopedic & Muscular System: Current Research	2161-0533
Orthopedic Oncology	-
Osteoporosis & Physical Activity	2329-9509
Otolaryngology:Open Access	2161-119X
Otology & Rhinology	2324-8785
Pain & Relief	2167-0846
Pain Management & Medicine	-
Palliative Care & Medicine	2165-7386
Pancreatic Disorders & Therapy	2165-7092
Pediatric Care	-
Pediatric Dental Care	-
Pediatric Emergency Care and Medicine- Open Access	-
Pediatric Nephrology Practice	-
Pediatric Neurology and Medicine	-
Pediatric Nursing: Open Access	-
Pediatric Oncology: Open Access	-
Pediatric Physiotherapy	-
Pediatric Psychology and Psychiatry	-
Pediatrics & Therapeutics	2161-0665
Periodontics and Prosthodontics: Open Access	-
Pigmentary Disorders	2376-0427
Prevention Infection Control: Open Access	-
Preventive Medicine	-
Primary & Acquired Immunodeficiency Research	2324-853X
Prostate Cancer	-
Psoriasis & Rosacea Open Access	-
Psychiatry	2378-5756
Psychological Abnormalities in Children	2329-9525
Psychology & Psychotherapy	2161-0487
Pulmonary & Respiratory Medicine	2161-105x
Rare Disorders & Diseases	-
Regenerative Medicine	2325-9620
Reproductive Endocrinology & Infertility	-
Reproductive System & Sexual Disorders	2161-038x
Research & Reviews: Journal of Dental Sciences	2320-7949
Research & Reviews: Journal of Medical and Health Sciences	2319-9865
Research Journal of Biology	2322-0066
Sleep Disorders & Therapy	2167-0277
Sleep Disorders : Treatment & Care	2325-9639
Spine	2165-7939
Spine & Neurosurgery	2325-9701
Spine Research	-
Sports Medicine & Doping Studies	2161-0673
Sports Nutrition and Therapy	-
Steroids & Hormonal Science	2157-7536
Stroke Research & Therapy	-
Journal of Surgery [Jurnalul de Chirurgie]	1584-9341
Surgery: Current Research	2161-1076
The Headache Journal	-
The International Journal of Apitherapy	-
The Pancreas	1590-8577
Therapeutic Care and Physical Rehabilitation	-

Thrombosis and Circulation	-
Thyroid Disorders & Therapy	2167-7948
Translational Medicine	2161-1025
Transplant Reports : Open Access	-
Transplantation Technologies & Research	2161-0991
Trauma & Acute Care	-
Trauma & Treatment	2167-1222
Traumatic Stress Disorders & Treatment	2324-8947
Tropical Medicine & Surgery	2329-9088
Tumor Diagnostics and Reports	-
Universal Surgery	2254-6758
Vascular Medicine & Surgery	2329-6925
Vitiligo & Dermatomyositis	-
Voice Medicine & Surgery	-
Women's Health Care	2167-0420
Wound Medicine and Tissue Repair	-
Yoga & Physical Therapy	2157-7595

Microbiology

Advances in Influenza Research	-
Antimicrobial Agents	-
Antivirals & Antiretrovirals	1948-5964
Applied Microbiology: Open Access	-
Archives of Clinical Microbiology	1989-8436
Bacteriology and Parasitology	2155-9597
Clinical Infectious Diseases & Practice	-
Clinical Microbiology: Open Access	2327-5073
Colitis & Diverticulitis	-
Emerging Infectious Diseases	-
Fermentation Technology	2167-7972
Fibromyalgia: Open Access	-
Forensic Pathology	-
Hepatitis	-
Human Papillomavirus	-
Infectious Diseases and Diagnosis	-
Infectious Diseases and Therapy	2332-0877
Medical Microbiology & Diagnosis	2161-0703
Medical Mycology: Open Access	-
Meningitis	-
Mycobacterial Diseases	2161-1068
Pediatric Infectious Diseases: Open Access	-
Research & Reviews: Journal of Microbiology and Biotechnology	2320-3528
Research & Reviews: Journal of Inflammation	-
Research & Reviews: Journal of Pathology & Epidemiology	-
Virology & Mycology	2161-0517

Neuroscience

Addiction Research & Therapy	2155-6105
Alzheimers Disease & Parkinsonism	2161-0460
Autism-Open Access	2165-7890
Brain Disorders & Therapy	2168-975X
Child & Adolescent Behavior	2375-4494
Clinical & Experimental Neuroimmunology	-
Dementia & Mental Health	-
Epilepsy Journal	-
Insights in Clinical Neurology	-
International Journal of Neurorehabilitation	2376-0281
Multiple Sclerosis	2376-0389
Neurological Disorders	2329-6895
Neurology & Neurophysiology	2155-9562
Neurology and Neuroscience	2171-6625
Neuropsychiatry	-
Neuroscience & Clinical Research	-
Schizophrenia Journal	-

Health Care & Nursing

Advanced Practices in Nursing	-
Community & Public Health Nursing	-
Nursing & Care	2167-1168
Nursing & Clinical Research	-
Patient Care	-
Perioperative & Critical Intensive Care Nursing	-
Research & Reviews: Journal of Nursing and Health Sciences	-

Pharmaceutical Sciences

Advances in Pharmacoepidemiology & Drug Safety	2167-1052
Alcoholism & Drug Dependence	2329-6488
Bioanalysis & Biomedicine	1948-593X
Biochemistry & Pharmacology: Open Access Journal	2167-0501
Bioequivalence & Bioavailability	0975-0851
Biomarkers in Drug Development	2327-4441
Biomarkers Journal	-
Biomolecular Research & Therapeutics	2167-7956
Cardiovascular Pharmacology: Open Access	2329-6607
Clinical & Experimental Pharmacology	2161-1459
Clinical Pharmacology and Biopharmaceutics	2167-065X
Current Trends in Nutraceuticals	-
Developing Drugs	2329-6631
Diagnostic Techniques & Biomedical Analysis	-
Drug Designing: Open Access	2169-0138
Drug Metabolism & Toxicology	2157-7609
in Silico & in Vitro Pharmacology	-
Molecular Enzymology and Drug Targets	-
Molecular Pharmaceutics & Organic Process Research	2329-9053
Pharmaceutica Analytica Acta	2153-2435
Pharmaceutical Care & Health Systems	2376-0419
Pharmaceutical Microbiology	-
Pharmaceutical Regulatory Affairs: Open Access	2167-7689
Pharmaceutical Sciences & Emerging Drugs	-
Pharmaceutics & Drug Delivery Research	2325-9604
Pharmacoeconomics: Open Access	-
Pharmacogenomics and Pharmacoproteomics	2153-0645
Pharmacognosy & Natural Products	-
Pharmacokinetics & Experimental Therapeutics	-
Pharmacological Reports	-
Pharmacovigilance	2329-6887
Research & Reviews: Journal of Hospital and Clinical Pharmacy	-
Research & Reviews: Journal of Pharmaceutical Analysis	2320-0812
Research & Reviews: Journal of Pharmaceutical Quality Assurance	-
Research & Reviews: Journal of Pharmaceutics and Nanotechnology	2347-7857
Research & Reviews: Journal of Pharmacognosy and Phytochemistry	2321-6182
Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences	2320-1215
Virology & Antiviral Research	2324-8955

Physics

Astrophysics & Aerospace Technology	2329-6542
Research & Reviews: Journal of Pure and Applied Physics	2320-2459
Vortex Science and Technology	2090-8369

Social & Political Sciences

Anthropology	2332-0915
Arts and Social Sciences Journal	2151-6200
Civil & Legal Sciences	2169-0170
Forensic Anthropology	-
Global Media Journal	1550-7521
Intellectual Property Rights: Open Access	2375-4516
Mass Communication & Journalism	2165-7912
Political Science & Public Affairs	2332-0761
Research & Reviews: Journal of Educational Studies	-
Research & Reviews: Journal of Social Sciences	-
Socialomics	2167-0358
Sociology & Criminology	2375-4435

Veterinary Sciences

Animal Nutrition	-
Primatology	2167-6801
Research & Reviews: Journal of Veterinary Sciences	-
Research & Reviews: Journal of Zoological Sciences	2321-6190
Veterinary Science & Medical Diagnosis	2325-9590
Veterinary Science & Technology	2157-7579

Impact Factors* (IF)

Journal Name	Pubmed Short Name	Impact Factor
Biological Systems: Open Access	Biol Syst Open Access	0.76
Journal of Biotechnology & Biomaterials	J Biotechnol Biomater	1.94
Journal of Psychology & Psychotherapy	J Psychol Psychother	1.3
Advanced Techniques in Biology & Medicine	Adv Tech Biol Med	1.08
AIDS & Clinical Research	J AIDS Clin Res	2.7
Autism Open Access	Autism Open Access	3.52
Biochemistry & Physiology: Open Access	Biochem Physiol	1.03
Diversity Equality in Health & Care	Divers Equal Health Care	2.49
Drug Designing: Open Access	Drug Des	6
Fungal Genomics & Biology	Fungal Genom Biol	1.15
International Journal of Genomic Medicine	Int J Genomic Med	0.67
Journal of Addiction Research & Therapy	J Addict Res Ther	2.86
Journal of Alzheimers Disease & Parkinsonism	J Alzheimers Dis Parkinsonism	1.18
Journal of Fertilization: In Vitro	JFIV Reprod Med Genet	1
Journal of Genetic Syndromes & Gene therapy	J Genet Syndr Gene Ther	2.34
Journal of Microbial & Biochemical Technology	J Microb Biochem Technol	2.5
Journal of Nursing & Care	J Nurs Care	1.6
Journal of Osteoporosis and Physical Activity	J Osteopor Phys Act	0.66
Journal of Yoga & Physical Therapy	J Yoga Phys Ther	1.17
Molecular Biology	Mol Biol	1.85
Neurology & Neurophysiology	J Neurol Neurophysiol	0.77
Primary health care	Prim Health Care	1
Quality in Primary Care	Qual Prim Care	3.88
Tissue Science & Engineering	J Tissue Sci Eng	2.72
Biochemistry & Analytical Biochemistry	Biochem Anal Biochem	2.6
Molecular and Genetic Medicine	J Mol Genet Med	2.89
Advancements in Genetic Engineering	Adv Genet Eng	1
Enzyme Engineering	Enz Eng	2.3
Depression and Anxiety	J Depress Anxiety	1
Human Genetics & Embryology	Human Genet Embryol	1.2
Current Synthetic and Systems Biology	Curr Synthetic Sys Biol	0.8
Hereditary Genetics: Current Research	Hereditary Genet	1.2
International Journal of Emergency Mental Health and Human Resilience	Int J Emerg Ment Health	6.5
Spine	J Spine	1.9
Cloning & Transgenesis	Clon Transgen	1.5
Journal of Medical Microbiology & Diagnosis	J Med Microb Diagn	1.9
Biosensors Journal	Biosens J	0.33
Defense Management	J Def Manag	0.5
Review of Public Administration and Management	Review Pub Administration Manag	0.2
Single cell biology	Single Cell Biol	1
Gerontology & Geriatric Research	J Gerontol Geriatr Res	1
Neuroinfectious Diseases	J Neuroinfect Dis	2.4
Cell Science & Therapy	J Cell Sci Ther	1.37
Molecular Biomarkers & Diagnosis	J Mol Biomark Diagn	2.1
Brain Disorders & Therapy	Brain Disord Ther	1.6
Clinical Case Reports	J Clin Case Rep	1.2
Gene Technology	Gene Technol	0.83
Socialomics	J Socialomics	2.3
Journal of Trauma and Treatment	J Trauma Treat	0.6
Translational Biomedicine	Transl Biomed	1.06
Journal of Neurology and Neuroscience	J Neurol Neurosci	0.88
Research & Reviews: Journal of Botanical Sciences	J Bot Sci	0.33
Journal of Psychiatry	J Psychiatry	2.32
Anaplastology	Anaplastology	0.73
Tropical Medicine & Surgery	Trop Med Surg	0.4
Orthopedic & Muscular System: Current Research	Orthop Muscular Syst	0.32
Pediatrics & Therapeutics	Pediat Therapeut	1.32
Sports Medicine & Doping Studies	J Sports Med Doping Stud	1.45
Journal of Oral Hygiene & Health	J Oral Hyg Health	0.52
Emergency Medicine	Emerg Med (Los Angel)	0.875
Journal of Transplantation Technologies & Research	J Transplant Technol Res	1.39
Journal of Hypertension: Open Access	J Hypertens (Los Angel)	0.92
International Journal of Waste Resources	Int J Waste Resour	1.95
Surgery: Current research	Surgery Curr Re	0.587
Oral Health and Dental Management	Oral Health Dent Manag	1.23
International Journal of Advancement technology	Int J Adv Tech	5.08
Translational Medicine	Transl Med (Sunnyvale)	1.312
Air and Water Borne Diseases	Air Water Borne Diseases	0.6
Journal of Coastal Zone Management	J Coast Zone Manag	0.54
Biology and Medicine	Biol Med (Aligarh)	3.07
Journal of Bioterrorism and Biodefense	J Bioterror Biodef	0.38
Journal of Tropical Diseases & Public Health	J Trop Dis	0.83
Journal of Surgery	Journal of Surgery [Jurnalul de chirurgie]	0.08
Nephrology & Therapeutics	J Nephrol Ther	0.318
Journal of Fundamentals of Renewable Energy and Applications	J Fundam Renewable Energy Appl	1.41
Advances in Pharmacoepidemiology & Drug Safety	Adv Pharmacoepidemiol Drug Saf	1.37
Bioanalysis & Biomedicine	J Bioanal Biomed	1.67
Biochemistry & Pharmacology: Open Access	Biochem Pharmacol (Los Angel)	2.09
Bioequivalence & Bioavailability	J Bioequiv Availab	1.88
Biomolecular Research & Therapeutics	J Biomol Res Ther	1.67
Cardiovascular Pharmacology: Open Access	Cardiol Pharmacol	1.77
Clinical & Experimental Pharmacology	Clin Exp Pharmacol	1.83
Clinical Pharmacology & Biopharmaceutics	Clin Pharmacol Biopharm	1.69
Data Mining in Genomics & Proteomics	J Data Mining Genomics Proteomics	2
Drug Metabolism & Toxicology	J Drug Metab Toxicol	1.37
Ergonomics	J Ergonomics	1.38
Glycomics & Lipidomics	J Glycomics Lipidomics	1.82
Health & Medical Informatics	J Health Med Inform	1.98
Metabolomics: Open Access	Metabolomics (Los Angel)	3.03
Nanomedicine & Biotherapeutic Discovery	J Nanomedine Biotherapeutic Discov	2.69
OMICS Journal of Radiology	OMICS J Radiol	0.54
Pharmaceutica Analytica Acta	Pharm Anal Acta	1.83
Pharmaceutical Regulatory Affairs: Open Access	Pharm Regul Aff	1.88
Pharmacogenomics & Pharmacoproteomics	J Pharmacogenomics Pharmacoproteomics	1.69
Pharmacovigilance	J Pharmacovigil	2.65
Phylogenetics & Evolutionary Biology	J Phylogenetics Evol Biol	2.76
Proteomics & Bioinformatics	J Proteomics Bioinform	2.55
Advances in Automobile Engineering	Adv Automob Eng	1.750
Advances in Robotics & Automation	Adv Robot Autom	0.813
Arts and Social Sciences Journal	Arts Social Sci J	1.231
Bioceramics Developments and Applications	Bioceram Dev Appl	0.958
Business & Financial Affairs	J Bus & Fin Aff	2.000
Generalized Lie Theory and Applications	J Generalized Lie Theory Appl	1.750
Irrigation & Drainage Systems Engineering	Irrigat Drainage Sys Eng	4.286
Industrial Engineering & Management	Ind Eng Manage	0.474
Aeronautics & Aerospace Engineering	J Aeronaut Aerospace Eng	1.407
Applied & Computational Mathematics	J Appl Computat Math	0.581
Architectural Engineering Technology	J Archit Eng Tech	1.071
Accounting & Marketing	J Account Mark	0.500
Aquaculture Research & Development	J Aquac Res Development	1.272
Bioengineering & Biomedical Science	J Bioeng Biomed Sci	1.235
Biometrics & Biostatistics	J Biomet Biostat	1.272
Biosensors & Bioelectronics	J Biosens Bioelectron	2.137
Civil & Environmental Engineering	J Civil Environ Eng	1.294
Cytology & Histology	J Cytol Histol	0.569
Civil & Legal Sciences	J Civil Legal Sci	0.286
Ecosystem & Ecography	J Ecosyst Ecogr	1.806
Electrical & Electronic Systems	J Elec Electron Syst	0.533
Earth Science & Climatic Change	J Earth Sci Clim Change	2.082
Geography & Natural Disasters	J Geogr Nat Disast	0.800
Hotel & Business Management	J Hotel Bus Manage	1.600
Information Technology & Software Engineering	J Inform Tech Soft Engg	2.789
Molecular Imaging & Dynamics	J Mol Imaging Dynam	2.091

Earth Science & Climatic Change	J Earth Sci Clim Change	2.082
Geography & Natural Disasters	J Geogr Nat Disast	0.800
Hotel & Business Management	J Hotel Bus Manage	1.600
Information Technology & Software Engineering	J Inform Tech Soft Engg	2.789
Molecular Imaging & Dynamics	J Mol Imaging Dynam	2.091
Petroleum & Environmental Engineering	J Pet Environ Biotechnol	2.839
Stock & Forex Trading	J Stock Forex Trad	0.300
Textile Science & Engineering	J Textile Sci Eng	0.667
Tourism & Hospitality	J Tourism Hospit	1.190
Telecommunications System & Management	J Telecommun Syst Manage	0.800
Physical Mathematics	J Phys Math	4.500
Nanomedicine & Nanotechnology	J Nanomed Nanotechnol	4.68
Arabian Journal of Business and Management Review	Arab J Bus Manage Rev	1.42
Research and Reviews: Journal of Engineering and Technology	Engineering and Technology	0.14
Journal of Material Sciences & Engineering	J Material Sci Eng	1.31
Journal of Mass Communication & Journalism	J Mass Communicat Journalism	0.62
Journal of Powder Metallurgy & Mining	J Powder Metall Min	0.71
Journal of Applied Mechanical Engineering	J Appl Mech Eng	1.65
Archives of Clinical Microbiology		0.35
Dentistry	Dentistry	1.22
Journal of Diabetes & Metabolism	J Diabetes Metab	1.77
Otolaryngology: Current Research	Otolaryngol (Sunnyvale)	0.22
Journal of Metabolic Syndrome	J Metabolic Synd	1.27
Journal of Primatology	J Primatol	0.53
Journal of Thyroid Disorders & Therapy	Thyroid Disorders Ther	0.43
Jounal of Novel Physiotherapies	J Nov Physiother	1.24
Journal of Stem Cell Research & Therapy	J Stem Cell Res Ther	2.78
Anatomy & Physiology: Current Research	Anat Physiol	1
Pancreatic Disorders & Therapy	Pancreat Disord Ther	0.54
Journal of Cancer Science & Therapy	J Cancer Sci Ther	4.203
Journal of Biomedical Sciences		0.2
Journal of Nutritional Disorders & Therapy	J Nutr Disord Ther	1.46
Medical & Surgical Urology	Med Surg Urol	0.3
Journal of Biochips & Tissue Chips	J Biochip Tissue Chip	1.7
Journal of Liver	J Liver	0.08
Journal of Family Medicine and Medical Research	Fam Med Med Sci Res	0.78
Gynecology & Obstetrics	Gynecol Obstet (Sunnyvale)	0.52
Journal of Integrative Oncology	J Integr Oncol	1.67
Journal of Neonatal Biology	J Neonatal Biol	0.55
Journal of Glycobiology	J Glycobiology	0.8
Journal of Blood & Lymph	J Blood Lymph	0.12
Journal of Arthritis	J Arthritis	1.87
Journal of Membrane Science & Technology	J Membra Sci Technol	1.18
Medicinal Chemistry	Med Chem (Los Angeles)	2.64
Journal of Physical Chemistry & Biophysics	J Phys Chem Biophys	0.75
Organic Chemistry: Current Research	Organic Chem Curr Res	1.94
Journal of Bioprocessing & Biotechniques	J Bioprocess Biotech	1.74
Journal of Environmental & Analytical Toxicology	J Environ Anal Toxicol	2.58
Journal of Chemical Engineering & Process Technology	J Chem Eng Process Technol	1.21
Journal of Computer Science & Systems Biology	J Comput Sci Syst Biol	1.62
Journal of Analytical & Bioanalytical Techniques	J Anal Bioanal Tech	2.16
Journal of Plant Biochemistry & Physiology	J Plant Biochem Physiol	2.28
Journal of Chromatography & Separation Techniques	J Chromatogr Sep Tech	1.78
Journal of Thermodynamics & Catalysis		0.91
Community Medicine & Health Education	J Community Med Health Educ	1.27
Epidemiology: Open Access	Epidemiology (Sunnyvale)	1.35
Obesity & Weight Loss Therapy	J Obes Weight Loss Ther	0.94
Pain & Relief	J Pain Relief	1.14
Palliative Care & Medicine	J Palliat Care Med	0.88
Steroids & Hormonal Science	J Steroids Horm Sci	0.65
Gastrointestinal & Digestive System	J Gastrointest Dig Syst	0.43
Hair: Therapy & Transplantation		0.6
Andrology	Andrology (Los Angel)	1.16
Endocrinology & Metabolic Syndrome	Endocrinol Metab Syndr	1.12
Internal Medicine		2.48
Sleep Disorders & Therapy	J Sleep Disord Ther	0.5
Nuclear Medicine & Radiation Therapy	J Nucl Med Radiat Ther	0.88
Alternative & Integrative Medicine	Altern Integr Med	1.11
Pulmonary & Respiratory Medicine	J Pulm Respir Med	1.01
Occupational Medicine Health Affairs	Occup Med Health Aff	0.85
Reproductive System & Sexual Disorders	Reprod Syst Sex Disord	1.25
Medical Diagnostic Methods		0.29
Blood Disorders & Transfusion	J Blood Disord Transfus	0.5
General Medicine	Gen Med (Los Angel)	0.86
Bioenergetics: Open Access	Bioenergetics	3.1
Chemotherapy: Open Access	Chemotherapy (Los Angel)	1.8
Clinical & Experimental Pathology	J Clin Exp Pathol	1.54
Carcinogenesis & Mutagenesis	J Carcinog Mutagen	1.9
Clinical Research & Bioethics	J Clinic Res Bioeth	0.95
Vaccines & Vaccination	J Vaccines Vaccin	1.8
Immunome Research	Immunome Res	7.1
Clinical & Experimental Ophthalmology	J Clin Exp Ophthalmol	1.11
Clinical & Experimental Dermotology Research	J Clin Exp Dermatol Res	0.5
Clinical & Experimental Cardiology	J Clin Exp Cardiolog	1.33
Clinical Microbiology: Open Access	Clin Microbiol	0.7
Anesthesia & Clinical research	J Anesth Clin Res	0.7
Mycobacterial Diseases	Mycobact Dis	0.9
Clinical Toxicology	J Clin Toxicol	1.39
Clinical Trials & Research	J Clin Trials	1.33
Antivirals & Antiretrovirals	J Antivir Antiretrovir	1.27
Fermentation Technology	Ferment Technol	3.44
Clinical & Cellular immunology	J Clin Cell Immunol	2.019
Allergy & Therapy	J Allergy Ther	0.762
Bacteriology & Parasitology	J Bacteriol Parasitol	2.025
Rheumatology: Current Research	Rheumatology (Sunnyvale)	1.522
Virology & Mycology	Virol Mycol	0.69
Clinics in Mother and Child Health	Clinics Mother Child Health	0.432
Womens Health Care	J Womens Health Care	0.79
Marine Science: Research & Development	J Marine Sci Res Dev	0.45
Plant Pathology & Microbiology	J Plant Pathol Microbiol	1.75
Geology & Geophysics	J Geol Geophys	0.91
FisheriesSciences	J Fisheries Sci	0.51
Fisheries and Aquaculture Journal	Fish Aquac J	0.69
Bioremediation & Biodegradation	J Bioremediat Biodegrad	2.1
Advances in Crop Science and Technology	Adv Crop Sci Tech	0.39
Journal of Remote Sensing & GIS	J Geophys Remote Sens	0.77
Biofertilizers & Biopesticides	J Biofertil Biopestic.	1.19
Hydrology: Current Research	Hydrol Current Res	1.12
Probiotics & Health	J Prob Health	0.69
Veterinary Science & Technology	J Veterinar Sci Technolo	2.5
Medicinal & Aromatic Plants	Med Aromat Plants	2.02
Forest Research	Forest Res	1.69
International Journal of Sensor Networks and Data Communications	Sensor Netw Data Commun	1.66
Innovative Energy Policies	Innov Energ Policies	0.88
Biodiversity & Endangered Species	J Biodivers Endanger Species	0.25
Biosafety	Biosafety	0.49
Agrotechnology	Agrotechnol	0.69
Journal of Traditional Medicine and Clinical Naturopathy	J Tradition Med Clin Naturopth	0.49
Nutrition & Food Sciences	J Nutr Food Sci	1.14
Entomology, Ornithology & Herpetology	Entomol Ornithol Herpetol	1.26

Impact Factor Calculation:

Impact Factor was established by dividing the number of articles published in 2012 and 2013 with the number of times they are cited in 2014 based on Google search and the Scholar Citation Index database. If 'X' is the total number of articles published in 2012 and 2013, and 'Y' is the number of times these articles were cited in indexed journals during 2014 than, impact factor = Y/X







4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Supporting Journals

Rare Diseases Congress-2018


Supporting Journals

Journal of Genetic Syndromes & Gene Therapy
www.omicsonline.org/genetic-syndromes-gene-therapy.php

Journal of Clinical Infectious Diseases & Practice
www.omicsonline.org/clinical-infectious-diseases-practice.php

Journal of Clinical Trials
www.omicsgroup.org/journals/clinical-trials.php

Journal of Neuroinfectious Diseases
www.omicsonline.com/open-access/neuroinfectious-diseases.php



Agri, Food, Aqua & Veterinary





21st Euro-Global Summit on Food and Beverages
March 08-10, 2018 Berlin, Germany
E: eurofood@foodtechconferences.com
W: food.global-summit.com/europe

10th Euro-Global Summit on Aquaculture & Fisheries
May 28-29, 2018 London, UK
E: aquaeurope@aquaconferences.com
W: aquaculture-fisheries.conferenceseries.com/europe

8th International Conference on
Food Safety & Regulatory Measures
June 11-12, 2018 Barcelona, Spain
foodsafety@foodtechconferences.com
W: foodsafety-hygiene.conferenceseries.com

11th International Veterinary Congress
July 02-03, 2018 Berlin, Germany
E: veterinary@veterinaryseries.com
W: veterinary.conferenceseries.com

3rd International Conference on
Food and Beverage Packaging
July 16-18, 2018 Rome, Italy
E: foodpackaging@foodtechconferences.com
W: foodpackaging.conferenceseries.com

5th Annual Congress on
Plant & Soil Science
August 16-17, 2018 London, UK
E: plant-soil@plantscienceconferences.com
W: plantscience-biology.agriconferences.com

13th International Conference on
Agriculture & Horticulture
September 10-12, 2018 Zurich, Switzerland
E: agri@foodtechconferences.com
W: agriculture-horticulture.conferenceseries.com

21st International Conference on
Food Technology & Processing
October 02-04, 2018 London, UK
E: foodtechnology@foodtechconferences.com
W: foodtechnology.conferenceseries.com

22nd International Conference on
Food Processing & Analysis
October 11-13, 2018 Moscow, Russia
E: eurofoodprocessing@foodtechconferences.com
W: foodprocessing.foodtechconferences.org

6th Global Summit on Plant Science
October 29-30, 2018 Valencia, Spain
E: plantscience@plantscienceconferences.com
W: plantscience.global-summit.com

9th European Food Safety & Standards Conference
November 29-30, 2018 Dublin, Ireland
E: eurofoodsafety@foodtechconferences.com
W: foodsafety-hygiene.conferenceseries.com/europe

3rd International Conference on Food Microbiology
November 26-28, 2018 Dublin, Ireland
E: foodmicrobiology@foodtechconferences.com
W: foodmicrobiology.conferenceseries.com

Alternative Healthcare





9th International Conference and Exhibition on
Chinese Medicine, Ayurveda & Acupuncture
March 12-13, 2018 Barcelona, Spain
E: chinesemedicine@healthconferences.org
W: chinesemedicine.conferenceseries.com


5th International Conference and Exhibition on
Herbal and Traditional Medicine
June 14-15, 2018 Rome, Italy
E: herbalmedicine@annualconferences.org
W: herbalconference.annualcongress.com

8th International Conference & Exhibition on
Traditional & Alternative Medicine
November 01-03, 2018 Valencia, Spain
E: traditionalmedicine@healthconferences.org
W: traditionalmedicine.conferenceseries.com






Biochemistry





3rd International Conference on
Enzymology and Molecular Biology
March 05-06, 2018 London, UK
E: enzymology@annualconferences.org
W: enzymology.conferenceseries.com

13th International Conference on
Metabolomics and Systems Biology
June 11-12, 2018 London, UK
E: eurometabolomics@annualconferences.org
W: europe.metabolomicsconference.com

4th International Conference on
Lipid Science & Technology
July 23-24, 2018 Birmingham, UK
E: lipids@biochemconferences.org
W: lipids.conferenceseries.com

4th Glycobiology World Congress
September 17-19, 2018 Rome, Italy
E: glycobiology@annualconferences.org
W: glycobiology.conferenceseries.com

14th International Conference on Structural Biology
September 24-26, 2018 Berlin, Germany
E: structuralbiology@biochemconferences.org
W: structuralbiology.conferenceseries.com

12th International Conference on
Advancements in Bioinformatics and Drug Discovery
November 29-30, 2018 Dublin, Ireland
E: bioinformatics@annualconferences.org
W: bioinformatics.conferenceseries.com

12th International Conference and Expo on
Proteomics and Molecular Medicine
November 26-28, 2018 Dublin, Ireland
E: proteomics@annualconferences.org
W: www.proteomicsconference.com

Cardiology





24th Annual Cardiologists Conference
June 11-13, 2018 Barcelona, Spain
E: cardiologists@cardiologyconference.org
W: annualmeeting.conferenceseries.com/cardiologists

26th Annual Conference on
Clinical & Medical Case Reports in Cardiology
July 05-06, 2018 Berlin, Germany
E: cardiologycasereports@annualconferences.org
W: casereports.cardiologymeeting.com

3rd International Conference on
Cardiovascular Medicine and Cardiac Surgery
July 05-06, 2018 Berlin, Germany
E: cardiovascular@cardiologyconference.org
W: cardiovascular.conferenceseries.com

4th International Conference on
Hypertension & Healthcare
September 10-11, 2018 Zurich, Switzerland
E: hypertension@cardiologymeetings.com
W: hypertension.conferenceseries.com

27th European Cardiology Conference
October 22-24, 2018 Rome, Italy
E: eurocardiology@cardiologyconference.org
W: cardiology.conferenceseries.com/europe

29th World Cardiology Conference
November 19-20, 2018 Edinburg, Scotland
E: worldcardiology@annualconferences.org
W: worldcardiology.conferenceseries.com






Chemical Engineering





8th International Conference on
Petroleum Engineering
May 17-18, 2018 Rome, Italy
E: petroleumengineering@chemseries.com
W: petroleumengineering.conferenceseries.com

8th World Congress on
Biopolymers
June 28-30, 2018 Berlin, Germany
E: biopolymercongress@chemseries.com
W: biopolymers.conferenceseries.com

11th World Bioenergy Congress and Expo
July 02-04, 2018 Berlin, Germany
E: bioenergy@chemseries.com
W: bioenergy.conferenceseries.com

12th Global Summit and Expo on
Biomass and Bioenergy
September 04-05, 2018 Zurich, Switzerland
E: eurobiomass@chemseries.com
W: materials.conferenceseries.com

13th World Congress on
Biofuels and Bioenergy
September 04-06, 2018 Zurich, Switzerland
E: biofuelscongress@chemseries.com
W: biofuels-bioenergy.conferenceseries.com/europe

5th International Conference on
Advances in Chemical Engineering & Technology
October 04-05, 2018 London, UK
E: eurochemengineering@chemseries.com
W: chemicalengineering.conferenceseries.com/europe

Chemistry





4th European Organic Chemistry Congress
March 01-03, 2018 London, UK
E: euroorganicchemistry@chemistryconference.org
W: organicchemistry.conferenceseries.com/europe

6th International Conference and Exhibition on
Materials Science and Chemistry
May 17-18, 2018 Rome, Italy
E: materialschemistry@chemistryconference.org
W: materialschemistry.conferenceseries.com

4th International Conference on
Electrochemistry
June 11-12, 2018 Rome, Italy
E: electrochemistry@chemistryconference.org
W: electrochemistry.conferenceseries.com

10th World Congress on
Medicinal Chemistry and Drug Design
June 14-15, 2018 Barcelona, Spain
E: medicinalchemistry@chemistryconference.org
W: medicinalchemistry.pharmaceuticalconferences.com/europe

7th World Congress on
Mass Spectrometry
June 20-22, 2018 Rome, Italy
E: euromassspectrometry@chemistryconference.org
W: massspectra.com/europe

8th European Chemistry Congress
June 21-23, 2018 Paris, France
E: eurochemistry@conferenceseries.net
W: chemistry.conferenceseries.com/europe

6th International Conference and Exhibition on
Advances in Chromatography & HPLC Techniques
August 02-03, 2018 Barcelona, Spain
E: hplc@chemistryconference.org
W: hplc.conferenceseries.com






7th International Conference and Exhibition on
Pain Research and Management
September 04-05, 2018 Zurich, Switzerland
E: painmanagement@chemistryconference.org
W: painmanagement.conferenceseries.com

9th International Conference and Expo on
Separation Techniques
September 13-14, 2018 Zurich, Switzerland
E: separationtechniques@chemistryconference.org
W: separationtechniques.conferenceseries.com

8th International Conference on
Environmental Chemistry and Engineering
September 20-22, 2018 Berlin, Germany
E: environmentalchemistry@chemistryconference.org
W: environmentalchemistry.conferenceseries.com

5th International Conference on
Physical and Theoretical Chemistry
October 11-13, 2018 Edinburgh, Scotland
E: physicalchemistry@chemistryconference.org
W: physicalchemistry.conferenceseries.com

3rd International Conference on
Pharmaceutical Chemistry
October 29-31, 2018 Brussels, Belgium
E: pharmaceuticalchemistry@pharmaceuticalconferences.org
W: pharmaceuticalchemistry.conferenceseries.com

Dentistry





21st Annual World Denal Summit
February 26-28, 2018 Paris, France
E: dentalworld@dentalcongress.com
W: worlddental.conferenceseries.com

25th International Conference on
Dental Education
April 9-10,2018 Amsterdam, Netherlands
E: dentaleducation@annualconferences.org
W: dentaleducation.dentalcongress.com

24th Global Dentists and Pediatric Dentistry Annual Meeting
June 11-12, 2018 London, UK
E: dentists@dentalcongress.com
W: annualmeeting.conferenceseries.com/dentists/

25th World Congress on
Dentistry and Oral Health
July 09-10, 2018 Berlin, Germany
E: dentistrycongress@dentistryconferences.com
W: dentalevent.conferenceseries.com

23rd International Conference on
Dentistry and Dental Materials
July 19-20, 2018 Rome, Italy
E: dentalmaterials@dentalcongress.com
W: dentalmaterials.dentistryconferences.com

4th International Conference on
Dental and Clinical Dentistry
September 10-11, 2018 Copenhagen, Denmark
E: clinicaldentistry@dentistryconferences.com
W: clinicaldentistry.dentistryconferences.com

3rd International Conference on
Advanced Dental Education
November 15-16, 2018 Edinburgh, Scotland
E: advdentaleducation@annualconferences.org
W: advanced-dental-education.dentistryconferences.com

26th Euro Congress and Expo on
Dental and Oral Health
December 10-11, 2018 Rome, Italy
E: eurodentalcongress@dentistryconferences.com
W: www.dentalcongress.com/europe

Dermatology





17th European Dermatology Congress
March 01-03, 2018 Paris, France
E: dermatologycongress@dermatologyconference.org
d W: ermatology.conferenceseries.com/europe






13th Global Dermatologists Congress
July 23-24, 2018 Moscow, Russia
E: dermatologists@dermatologyconference.org
W: annualmeeting.conferenceseries.com/dermatologists

14th International Conference and Exhibition on
Cosmetic Dermatology and Hair Care
August 13-14, 2018 Madrid, Spain
E: cosmeticdermatology@dermatologyconference.org
W: cosmeticdermatology.conferenceseries.com

Diabetes







17th Global Diabetes Conference & Nursing Care
March 08-09, 2018 Paris, France
E: globaldiabetes@conferenceseries.net
W: globaldiabetes.conferenceseries.com

27th European Diabetes Congress
June 20-21, 2018 Rome, Italy
E: eurodiabetes@endocrineconferences.com
W: www.diabetesexpo.com/europe

3rd International Conference on
Metabolic Syndrome & Clinical Management
June 18-19 , 2018 Dublin, Ireland
E: metabolicsyndrome@endocrineconferences.com
W: metabolicsyndromes.conferenceseries.com

29th International Congress on
Prevention of Diabetes and Complications
September 27-28, 2018 Berlin, Germany
E: diabetesmeeting@endocrineconferences.org
W: diabetesmeeting.conferenceseries.com

13th European Diabetes and Endocrinology Congress
November 26-27, 2018 Dublin, Ireland
E: euroendocrinology@endocrineconferences.com
W: europe.endocrineconferences.com

Engineering





2nd International Conference on
3D Printing Technology and Innovations
March 19-20, 2018 London, UK
E: 3dprinting@conferenceseries.net
W: 3dprinting.conferenceseries.com

4th International Conference and Business Expo on
Wireless, Telecommunication & IoT
May 28-29 2018 London, UK
E: wireless@enggconferences.com
W: wirelesscommunication.conferenceseries.com

2nd World Congress on
Wind and Renewable Energy
June 14-15, 2018 London, UK
E: windenergy@enggconferences.com
W: winenergy.conferenceseries.com

3rd International Conference on
Power and Energy Engineering
June 18-19, 2018 Rome, Italy
E: powerengineering@annualconferences.org
W: power-energy.conferenceseries.com

4th International Conference and Exhibition on
Satellite & Space Missions
June 18-20, 2018 Rome, Italy
E: satellite@annualconferences.org
W: satellite.conferenceseries.com

5th International Conference on
Big Data Analysis and Data Mining
June 20-21, 2018 Rome, Italy
E: bigdata@enggconferences.com
W: datamining.conferenceseries.com

4th Global Summit and Expo on
Multimedia & Artificial Intelligence
July 19-21,2018 Rome, Italy
E: multimedia@enggconferences.com
W: multimedia.global-summit.com






International Conference on
Aerospace and Aerodynamics
August 02-03, 2018 Barcelona, Spain
E: aerospace@annualconferences.org
W: aerospace-engineering.conferenceseries.com

9th Euro Biosensors and Bioelectronics conference
September 13-14, 2018 London, UK
E: eurobiosensors@conferenceseries.net
W: biosensors.conferenceseries.com/europe

5th International Conference and Exhibition on
Automobile Engineering
September 20-21, 2018 Rome, Italy
E: automobile@enggconferences.com
W: automobile.conferenceseries.com/europe

International Conference on
Cloud Computing and Data Analysis
September 06-07, 2018 London, UK
E: cloudcomputing@annualconferences.org
W: cloud-computing.conferenceseries.com

3rd International Conference on
Battery and Fuel Cell Technology
September 10-11, 2018 London, UK
E: batterytech@enggconferences.com
W: batterytech.conferenceseries.com

2nd International Conference on
Membrane Science and Technology
September 13-14, 2018 London, UK
E: membranescience@annualconferences.org
W: membranescience.conferenceseries.com

2nd International Conference on
Mechatronics, Automation and Control Systems
September, 17-18, 2018 Berlin, Germany
E: mechatronics@enggconferences.com
W: mechatronics.conferenceseries.com

3rd International Conference on
Fluid Dynamics & Aerodynamics
October 25-26, 2018 Berlin, Germany
E: fluiddynamics@enggconferences.com
W: fluid-aerodynamics.global-summit.com

International Conference on
Agricultural Engineering and Food Security
November 12-13,2018 Frankfurt, Germany
E: foodsecurity@annualconferences.com
W: agri-foodsecurity.agriconferences.com

3rd International Conference on
Design and Production Engineering
December 03-04, Valencia, Spain
E: productionengineering@annualconferences.org
W: design-production.conferenceseries.com

Environmental Sciences





World Conference on Ecology
March 19-20, 2018 Berlin, Germany
E: ecology@annualconferences.org
W: ecology.conferenceseries.com

8th World Congress and Expo on
Recycling
June 25-26, 2018 Berlin, Germany
E: recyclingexpo@conferenceseries.net
W: recycling.conferenceseries.com

5th World Congress and Expo on
Green Energy
June 14-16 ,2018 London, UK
E: greenenergycongress@earthscienceconferences.com
W: greenenergy.conferenceseries.com/europe

4th International Conference on
Pollution Control and Sustainable Environment
July 26-28, 2018 Rome, Italy
E: pollutioncontrol@conferenceseries.net
W: pollutioncontrol.conferenceseries.com

5th World Conference on
Climate Change
October 04-06, 2018 London, UK
E: climatechange@annualconferences.org
W: climatechange.conferenceseries.com






Gastroenterology







12th Global Gastroenterologists Meeting
March 15-16, 2018 Barcelona, Spain
E: gastro@gastroconferences.org
W: gastro.conferenceseries.com

6th World Congress on
Hepatitis & Liver Diseases
June 18-20, 2018 Dublin, Ireland
E: hepatitis@gastroconferences.com
W: hepatitis.conferenceseries.com

13th Euro-Global Gastroenterology Conference
August 20-21, 2018 Rome, Italy
E: gastrocongress@gastroconferences.com
W: gastroenterology.conferenceseries.com/europe

3rd International conference on
Digestive Diseases
October 22-24, 2018 Berlin, Germany
E: digestivediseases@gastroconferences.com
W: digestivediseases.conferenceseries.com

Genetics and Molecular Biology

7th International Conference and Exhibition on
Cell and Gene Therapy
March 15-17, 2018 London,UK
E: celltherapy@conferenceseries.net
W: cellgenetherapy.conferenceseries.com

20th Global Congress on
Biotechnology
March 05-07, 2018 London, UK
E: biotechcongress@geneticconferences.com
W: biotechnology.conferenceseries.com

6th International Conference on
Integrative Biology
May 21-23, 2018 Barcelona, Spain
E: integrativebiology@conferenceseries.net
W: integrativebiology.conferenceseries.com

10th International Conference on
Genomics and Molecular Biology
May 21-23, 2018 Barcelona, Spain
E: genomics@conferenceseries.net |
W: genomics.conferenceseries.com

4th International Conference on
Synthetic Biology and Tissue Engineering
June 11-12, 2018 Rome, Italy
E: syntheticbiology@conferenceseries.net
W: syntheticbiology.conferenceseries.com



4th International Conference on
Bioscience
July 02-03, 2018 Vienna, Austria
E: bioscience@conferenceseries.net
W: bioscience.conferenceseries.com

10th Annual Conference on
Stem Cell and Regenerative Medicine
August 13-14, 2018 London, UK
E: stemcellcongress@conferenceseries.net
W: stemcell-regenerativemedicine.conferenceseries.com

21st Euro Biotechnology Congress
October 11-12, 2018 Moscow, Russia
E: eurobiotechnology@geneticconferences.com
W: www.biotechnologycongress.com/europe

11th International Conference on
Tissue Engineering & Regenerative Medicine
October 18-20, 2018 Rome, Italy
E: regenerativemedicine@geneticconferences.com
W: tissuescience-regenerativemedicine

Geology and Earth Sciences


2nd Annual Congress on
Soil and Water Sciences
June 14-15, 2018 Dublin, Ireland
E: soilscience@annualconferences.org
W: soilscience.conferenceseries.com






4th International Conference on
GIS and Remote Sensing
September 27-28, 2018 Berlin, Germany
E: giscongress@earthscienceconferences.com
W: gis-remotesensing.conferenceseries.com/europe

Healthcare





3rd World Congress on
Public Health & Nutrition
February 26-28, 2018 London, UK
E: publichealthcongress@healthconferences.org
W: publichealth.global-summit.com

3rd World Congress on
Health Economics & Patient Safety
April 12-13, 2018 Amsterdam, Netherlands
E: healtheconomics@healthconferences.org
W: healtheconomics.global-summit.com

5th International Conference on
Tropical Medicine & Infectious Diseases
May 21-22, 2018 Barcelona, Spain
E: tropicalmedicine@healthconferences.org
W: tropicalmedicine.annualcongress.com

13th World Congress on
Healthcare & Technologies
June 14-15, 2018 Dublin, Ireland
E: healthcaresummit@healthconferences.org
W: healthcare.global-summit.com/europe

2nd International Conference on
Social Sciences & Interdisciplinary Studies
June 18-19, 2018 Rome, Italy
E: socialsciences@healthconferences.org
W: socialsciences.conferenceseries.com

6th International Conference on
Medical Informatics & Telemedicine
July 05-06, 2018 Berlin, Germany
E: medicalinformatics@healthconferences.org
W: medicalinformatics.conferenceseries.com

8th International Conference on
Geriatrics Gerontology & Palliative Nursing
July 30-31, 2018 Barcelona, Spain
E: geriatrics@healthconferences.org
W: geriatrics-gerontology.conferenceseries.com

3rd Internationl Conference on
General Practice & Primary Care
August 16-17, 2018 Madrid, Spain
E: generalpractice@healthconferences.org
W: generalpractice.conferenceseries.com

4th World Congress on Health Economics, Health Policy and Healthcare Management
September 13-14, 2018 Zurich, Switzerland
E: health-economics@healthconferences.org
W: healtheconomics.healthconferences.org

7th International Conference on
Epidemiology & Public Health
September 17-19, 2018 Rome, Italy
E: epidemiology@healthconferences.org
W: epidemiology.conferenceseries.com

3rd International Conference on
Environmental Health & Preventive Medicine
October 15-16, 2018 Warsaw, Poland
E: environmentalhealth@healthconferences.org
W: environmentalhealth.conferenceseries.com

3rd International Conference on
Advances in Skin, Wound Care and Tissue Science
October 18-19, 2018 Rome, Itlay
E: woundcongress@healthcarevents.com
W: woundcare.conferenceseries.com/europe

3rd International Conference on
Healthcare & Hospital Management
October 25-26, 2018 Athens, Greece
E: hospitalmanagement@healthcareevents.com
W: hospitalmanagement.conferenceseries.com

7th International Conference on
Medical & Nursing Education
October 29-30, 2018 Brussels, Belgium
E: medicaleducation@healthconferences.org
W: medicaleducation.conferenceseries.com








5th International Conference on
Healthcare and Hospital Management
December 03-05, 2018 Rome, Italy
E: hospitalmanagement@healthconferences.org
W: hospital-management.healthconferences.org

3rd International Conference on
Autoimmunity
November 26-27, 2018 Dublin, Ireland
E: autoimmunity@immunologyconferences.org
W: autoimmunity.conferenceseries.com

Immunology

Infectious Diseases




9th Molecular Immunology & Immunogenetics Congress
March 08-09, 2018 London, UK
E: molecularimmunology@immunologyconferences.org
W: molecularimmunology.conferenceseries.com

5th International Congress on
Infectious Diseases
March 01-02, 2018 Berlin, Germany
E: infectioncongress@infectiousconferences.com
W: infectioncongress.conferenceseries.com

9th European Immunology Conference
June 14-16, 2018 Rome, Italy
E: euroimmunology@conferenceseries.net
W: immunology.conferenceseries.com/europe

4th World Congress on
Rare Diseases and Orphan Drugs
June 11-12, 2018 Dublin, Ireland
E: rarediseasecongress@infectiousconferences.com
W: rarediseases.conferenceseries.com/europe

5th International Conference on
Parasitology
July 12-13, 2018 Paris, France
E: parasitology@immunologyconferences.org
W: parasitology.conferenceseries.com

4th International Conference on
Influenza and Zoonotic Diseases
July 02-03, 2018 Vienna, Austria
E: influenza@infectiousconferences.com
W: influenza.conferenceseries.com

10th International Conference on
Clinical and Cellular Immunology
August 06-07, 2018 Madrid, Spain
E: immunologyworld@annualconferences.org
W: immunology.immunologyconferences.org

9th International Conference on
Emerging Infectious Diseases
August 27-28, 2018 Zurich, Switzerland
E: emerginginfections@annualconferences.org
W: emerging-diseases.infectiousconferences.com

11th Annual Congress on
Immunology & Immunotechnology
September 13-14, 2018 Zurich, Swtizerland
E: immunologycongress@annualconferences.org
W: immunologycongress.immunologyconferences.org

6th World Congress on
Control and Prevention of HIV/AIDS, STDs & STIs
August 27-29, 2018 Zurich, Switzerland
E: std@infectiousconferences.com
W: globalhiv-aids-std.infectiousconferences.com

12th International Conference on
Allergy, Asthma & Clinical Immunology
October 01-02, 2018 Moscow, Russia
E: allergy@immunologyconferences.org
W: allergy.conferenceseries.com

10th Euro-Global Conference on Infectious Diseases
September 27-29, 2018 Rome, Italy
E: europe@infectiousconferences.com
W: infection.conferenceseries.com/europe






13th World Congress on
Infection Prevention and Control
October 11-12, 2018 Moscow, Russia
E: ipcc@infectiousconferences.com
W: infectionprevention.conferenceseries.com

7th International Chronic Obstructive
Pulmonary Disease Conference
October 22-23, 2018 Rome, Italy
E: copdconferences@annualconferences.org
W: copd.conferenceseries.com/europe

Materials Science





3rd Annual Conference and Expo on
Biomaterials
March 05-06, 2018 Berlin, Germany
E: biomaterials@materialsconferences.org
W: biomaterials.conferenceseries.com

16th International Conference on
Emerging Materials and Nanotechnology
March 22-23, 2018 London, UK
E: emergingmaterialscongress@materialsconferences.org
W: emergingmaterials.materialsconferences.com

4th International Conference and Expo on
Ceramics and Composite Materials
May 14-15, 2018 Rome, Italy
E: ceramics@materialsconferences.org
W: ceramics.conferenceseries.com

19th World Congress on
Materials Science and Engineering
June 11-13, 2018 Barcelona, Spain
E: materialscongress@materialsconferences.org
W: materialsscience.conferenceseries.com/europe

7th International conference on
Smart Materials and Structures
July 02-03, 2018 Vienna, Austria
E: smartmaterialscongress@annualconferences.org
W: smartmaterials.materialsconferences.com

20th International Conference on
Advanced Energy Materials and research
August 13-14, 2018 Dublin, Ireland
E: advancedenergymaterials@annualconferences.org
W: energymaterials.materialsconferences.com

21st International Conference on
Advanced Materials & Nanotechnology
September 04-06, 2018 Zurich, Switzerland
E: materials@materialsconferences.org
W: materials.conferenceseries.com

International Conference on
Advanced Materials and Simulations
September 11-12, 2018 University of Derby, UK
E: materialssimulation@materialsconferences.org
W: advanced-materials-simulation.materialsconferences.com

3rd International Conference on
Graphene, Carbon Nanotubes, and Nanostructures
September 17-18, 2018 Berlin, Germany
E: carboncongress@materialsconferences.org
W: carbon.materialsconferences.com

Microbiology





16th International Pharmaceutical Microbiology and
Biotechnology Conference
May 21-23, 2018 Vienna, Austria
E: pharmaceutical@microbiologyconferences.org
W: pharmaceuticalmicrobiology.conferenceseries.com/europe

10th International Virology Congress and Expo
July 02-04, 2018 Vienna, Austria
E: eurovirology@microbiologyconferences.org
W: virology.conferenceseries.com/europe

13th International Congress on
Microbial Interactions and Microbial Ecology
July 19-20, 2018 Rome, Italy
E: microbialinteraction@microbiologyconferences.org
W: microbialinteraction.conferenceseries.com

47th World Congress on Microbiology
September 10-11, 2018 London, UK
E: microbiology@microbiologyconferences.org
W: microbiology.conferenceseries.com/europe






9th international summit on
Clinical Microbiology
October 08-09, 2018 Zurich, Switzerland
E: microbiologysummit@microbiologyconferences.org
W: clinicalmicrobiology.conferenceseries.com/europe

5th World Congress and Expo on
Applied Microbiology
November 15-16, 2018 Frankfurt, Germany
E: appliedmicrobiology@microbiologyconferences.org
W: microbiology.conferenceseries.com

Nanotechnology





23rd International Conference on
Nanomaterials and Nanotechnology
March 15-16, 2018 London, UK
E: nanomaterials@nanotechconferences.org
W: nanomaterials.conferenceseries.com

24th World Nano Conference
May 07-08 | 2018 Rome, Italy
E: nano@nanotechconferences.org
W: nano.conferenceseries.com

25th Nano Congress for Future Advancements
August 16-17, 2018 Dublin, Ireland
E: nanocongress@nanotechconferences.org
W: nanocongress.conferenceseries.com

26th International Conference on
Advanced Nanotechnology
October 04-05, 2018 Moscow Russia
E: advancednano@nanotechconferences.org
W: advancednano.nanotechconferences.org

3rd World Congress and Expo on
Graphene and 2D Materials
November 26-28, 2018 Barcelona, Spain
E: graphene@nanotechconferences.org
W: graphene.conferenceseries.com/europe

28th International Conference on
Nanosciences and Nanotechnology
November 26-28, 2018 Barcelona, Spain
E: nanoscience@nanotechconferences.org
W: nanotechnology.conferenceseries.com

Nephrology






17th International Conference on
Nephrology & Urology
March 12-13, 2018 London, UK
E: nephrology-urology@annualconferences.org
W: nephrology-urology.nephroconferences.com

19th Global Nephrologists Annual Meeting
May 14-15, 2018 Rome, Italy
E: nephrologists@nephroconferences.com
W: annualmeeting.conferenceseries.com/nephrologists/

22nd European Nephrology Conference
October 15-16, 2018 Warsaw, Poland
E: euronephrology@nephroconferences.com
W: nephrology.conferenceseries.com/europe

Neuroscience





21st World Congress on Neurology and Therapeutics
March 15-17, 2018 London, UK
E: neurology@neuroconferences.com
W: neurologyconference.com






22nd International Conference on
Neurology & Neurophysiology
April 23-24, 2018 Rome, Italy
E: neurophysiology@neuroconferences.com
W: neurophysiology.conferenceseries.com

23rd International Conference on
Neurology and Neurosurgery
April 23-24, 2018 Rome, Italy
E: neurosurgery@neuroconferences.org
W: neurosurgery.conferenceseries.com

24th International Conference on
Neuroscience and Neurochemistry
May 21-22, 2018 Birmingham, UK
E: neurochemistry@neuroconferences.com
W: neurochemistry.conferenceseries.com

11th International Conference on
Alzheimers Disease & Dementia
May 24-25, 2018 Vienna, Austria
E: dementiacongress@neuroconferences.com
W: alzheimers-dementia.neurologyconference.com

3rd International Conference on Spine and Spinal Disorders
June 11-12, 2018 London, UK
E: spine@neuroconferences.com
W: spine.conferenceseries.com

25th World Congress on Neurology & Neuroscience
June 18-19, 2018 Dublin, Ireland
E: neurosciencecongress@neuroconferences.com
W: neuroscience.neurologyconference.com

27th Euro-Global Neurologists Meeting
July 23-25, 2018 Moscow, Russia
E: neurologistsconference@neuroconferences.com
W: neurologists.neurologyconference.com

11th International Conference on Vascular Dementia
July 23-25, 2018 Moscow, Russia
E: vasculardementiacongress@neuroconferences.com
W: vasculardementia.neurologyconference.com

7th World Congress on
Addictive Disorders & Addiction Therapy
July 16-18, 2018 London, UK
E: addiction@neuroconferences.com
W: addictiontherapy.conferenceseries.com/europe

26th European Neurology Congress
August 6-8, 2018 Madrid, Spain
E: neurologycongress@neuroconferences.com
W: neurologyconference.com/europe

4th International Conference on Epilepsy & Treatment
August 29-30, 2018 Zurich, Swtizerland
E: epilepsy@neuroconferences.com
W: epilepsytreatment.conferenceseries.com

4th World Congress on Parkinsons & Huntington Disease
August 29-30, 2018 Zurich, Swtizerland
E: parkinson@neuroconferences.com
W: parkinsons.neurologyconference.com

6th International Conference on
Brain Disorders and Therapeutics
September13-15, 2018 Copenhagen, Denmark
E: braindisorders@neuroconferences.com
W: braindisorders.conferenceseries.com

7th International Conference on Neurological Disorders & Stroke
September 20-21, 2018 Rome, Italy
E: strokecongress@neuroconferences.com
W: stroke.neurologyconference.com

27th International Conference on
Neurology and Cognitive Neuroscience
October 18-19, 2018 Warsaw, Poland
E: neurocognitive@neuroconferences.com
W: neurocognitivedisorders.conferenceseries.com

12th International Conference on
Alzheimer's Disease & Dementia
October 29-31, 2018 Valencia, Spain
E: dementia@neuroconferences.com
W: alzheimers-dementia.conferenceseries.com

4th International Conference on Spine Surgery
November 1-2, 2018 Brussels, Belgium
E: spinesurgeryconference@neuroconferences.com
W: spinalsurgery.neurologyconference.com

28th Global Neurologists Annual Meeting on
Neurology and Neurosurgery
November 1-3, 2018 Brussels, Belgium
E: neurologists@neuroconferences.com
W: annualmeeting.conferenceseries.com/neurologists






4th International Conference on Spine and Spinal Disorders
November 12-13, 2018 Frankfurt, Germany
E: spinecongress@neuroconferences.com
W: spine.conferenceseries.com/europe

4th International Conference on
Central Nervous System Disorders & Therapeutics
November 12-14, 2018 Edinburgh, Scotland
E: cns@neuroconferences.com
W: cns.conferenceseries.com

Nursing





47th Global Nursing & Healthcare Conference
March 01-03, 2018 London, UK
E: nursingglobal@nursingconference.com
W: global.nursingconference.com/europe

7th World Congress on Breast Cancer
May 10-11, 2018 Frankfurt, Germany
E: breastcancer@conferenceseries.net
W: breastcancer.conferenceseries.com

3rd International Conference on
Reproductive Health and Medicine
May 21-22, 2018 Vienna, Austria
E: reproductivemedicine@healthconferences.org
W: reproductivehealth.conferenceseries.com/europe

48th World Congress on
Advanced Nursing Research
June 14-15, 2018 Dublin, Ireland
E: nursingresearch@annualconferences.org
W: nursingresearch.nursingmeetings.com

2nd World Congress on
Patient Safety & Quality Healthcare
June 21-22, 2018 Dublin, Ireland
E: patientsafety@healthconferences.org
W: patientsafety.conferenceseries.com

49th International Congress on
Nursing Care Plan and Health
16 -18 July 2018 Rome, Italy
E: nursingcareplan@annualconferences.org
W: nursingcareplan.nursingmeetings.com

50th World Congress On Men in Nursing
July 16-17, 2018 Rome, Italy
mennursing@annualconferences.org
W: men.nursingmeetings.com

5th Annual Congress on
Emergency Nursing & Critical Care
July 16-17, 2018 London, UK
E: emergencynursing@annualconferences.org
W: emergency.nursingmeetings.com

26th Cancer Nursing & Nurse Practitioners Conference
July 16-17, 2018 London, UK
E: cancernursing@nursingconference.com
W: cancernursing.nursingconference.com

31st World Congress on
Advanced Nursing Practice
August 16-18, 2018 Madrid, Spain
E: nursingpractice@nursingconference.com
W: nursingpractice.nursingconference.com

29th International Conference on
Pediatric Nursing & Healthcare
August 16-17, 2018 Madrid, Spain
E: pediatricnursing@nursingconference.com
W: pediatric.nursingconference.com

17th World Congress on
Clinical Nursing and Practice
August 29-30, 2018 Zurich, Swtizerland
E: clinicalnursing@annualconferences.org
W: clinical.nursingmeetings.com

5th World Congress on
Midwifery & Women's Health
September 13-14, 2018 Frankfurt, Germany
E: euromidwifery@nursingconference.com
W: midwifery.conferenceseries.com/europe

24th World Nursing and Healthcare Conference
September 13-15, 2018 Copenhagen, Denmark
E: worldnursing@annualconferences.org
W: world.nursingconference.com






51st World Nursing Leadership & Management Conference
October 04-05, 2018 Moscow, Russia
E: nursingleadership@annualconferences.org
W: nursingleadership.nursingmeetings.com

5th International Conference on
Gynecology and Obstetrics
October 8-10, 2018- Zurich, Switzerland
E: gynecology@nursingconference.com
W: gynecology.conferenceseries.com

33rd Euro Nursing & Medicare Summit
October 8-10, 2018 Edinburgh, Scotland
E: euronursing@nursingconference.com
W: europe.nursingconference.com

27th World Nursing Education Conference
November 12-14, 2018 Frankfurt, Germany
E: nursingeducation@nursingconference.com
W: nursingeducation.nursingconference.com

Nutrition





15th International Conference on Clinical Nutrition
May 24-26, 2018 Vienna, Austria
E: clinicalnutrition@nutritionalconference.com
W: clinicalnutrition.conferenceseries.com

21st European Nutrition and Dietetics Conference
June 11-13, 2018 Dublin, Ireland
E: nutritioncongress@nutritionalconference.com
W: nutritionalconference.com/europe

14th International Congress on Advances in Natural Medicines, Nutraceuticals & Neurocognition
July 19-20, 2018 London, UK
E: nutraceuticals@nutritionalconference.com
W: nutraceuticals.pharmaceuticalconferences.com

6th International Conference on
Sports Nutrition & Fitness
August 16-17, 2018 Dublin, Ireland
E: sports-nutrition@annualconferences.org
W: sportsnutrition.nutritionalconference.com

17th World Congress on
Nutrition and Food Chemistry
September 13-15, 2018 London, UK
E: nutri-foodchemistry@nutritionalconference.com
W: nutrition-foodchemistry.conferenceseries.com

22nd European Nutritional Science Congress
November 26-27, 2018 Barcelona, Spain
E: nutritionalscience@nutritionalconference.com
W: nutritionalscience.nutritionalconference.com

Obesity






11th International Conference on
Childhood Obesity and Nutrition
March 15-16, 2018 Barcelona, Spain
E: childhoodobesity@annualconferences.org
W: childhoodobesity.conferenceseries.com

14th Euro Obesity and Endocrinology Congress
September 13-14, 2018 London, UK
E: euroobesity@obesityconference.org
W: obesity.nutritionalconference.com

Oncology & Cancer



12th World Hematologists Congress
March 15-16, 2018 London, UK
E: hematologists@oncologymeet.com
W: hematology.conferenceseries.com/europe

6th International Congress on
Gynecology & Gynecologic Oncology
July 23-24, 2018 Rome, Italy
E: gynecologyconference@annualconferences.org
W: gynecologyconference.annualcongress.com






29th Euro-Global Summit on
Cancer Therapy & Radiation Oncology
July 23-25, 2018 Rome, Italy
E: eurocancer@oncologyseries.com
W: cancer-radiationoncology.conferenceseries.com

28th Euro Congress on Cancer Science & Therapy
August 09-10, 2018 Madrid, Spain
E: cancerscience@oncologyseries.com
W: cancerscience.conferenceseries.com

4th World Congress on
Medical Imaging and Clinical Research
September 03-04, 2018 London, UK
E: medicalimaging@oncologyseries.com
W: clinical-medicalimaging.conferenceseries.com

4th International Congress on
Epigenetics and Chromatin
September 03-04, 2018 London, UK
E: epigenetics@oncologyseries.com
W: epigenetics.conferenceseries.com

3rd Cancer Diagnostics Conference & Expo
September 20-21, 2018 Berlin, Germany
E: cancerdiagnotics@oncologyseries.com
W: cancerdiagnostics.conferenceseries.com

36th World Cancer Conference
October 11-13, 2018 Zurich, Switzerland
E: worldcancer@annualconferences.org
W: cancer.global-summit.com

13th World Biomarkers Congress
November 29-30, 2018 Dublin, Ireland
E: worldbiomarkers@oncologyseries.com
W: molecular-cancer-biomarkers.conferenceseries.com

Ophthalmology





19th Ophthalmology Summit
Feb 26-27, 2018 Berlin Germany
E: ophthalmologysummit@ophthalmologyconferences.com
W: ophthalmologysummit.conferenceseries.com

3rd Global Pediatric Ophthalmology Congress
March 22-23, 2018 London, UK
E: pediatricophthalmology@ophthalmologyconferences.com
W: pediatricophthalmology.conferenceseries.com

2nd International Conference on
Cataract and Advanced Eye Care
June 14-16, 2018 Rome, Italy
E: cataract@ophthalmologyconferences.com
W: cataract.conferenceseries.com

2nd Global Meeting and Expo on
Vision Science & Eye
August 29-30, 2018 Zurich, Swizeland
E: visionscience@ophthalmologyconferences.com
W: visionscience.conferenceseries.com

3rd International Conference and Expo on
Optometry and Vision Science
October 8-9, 2018 Edinburg, Scotland
E: optometry@ophthalmologyconferences.com
W: optometry.conferenceseries.com

17th International Conference on
Clinical & Experimental Ophthalmology
October 1-3, 2018 Moscow, Russia
E: ophthalmology@ophthalmologyconferences.org
W: ophthalmology.conferenceseries.com

28th European Ophthalmology Congress
November 26-28, 2018 Dublin, Ireland
E: ophthalmologycongress@ophthalmologyconferences.com
W: ophthalmology.conferenceseries.com/europe

Pathology





13th International Conference on
Laboratory Medicine and Pathology
June 25-26, 2018 Berlin, Germany
E: laboratorymedicine@pathologyconferences.org
W: laboratorymedicine.conferenceseries.com

14th International Conference on
Surgical Pathology & Cancer Diagnosis
May 17-18, 2018 Rome, Italy
E: surgicalpathology@annualconferences.org
W: surgicalpathology.conferenceseries.com






8th European Conference on Predictive, Preventive, Personalized Medicine & Molecular Diagnostics
August 20-21, 2018 Rome, Italy
E: europersonalizedmedicine@conferneceseries.net
W: personalizedmedicine.conferenceseries.com/europe

Pediatrics





3rd International Conference on Pediatric Surgery
May 7-8, 2018 Frankfurt, Germany
E: pediatricsurgery@annualconferences.org
W: pediatricsurgery.conferenceseries.com

17th International Conference on Clinical Pediatrics
June 14-16, 2018 Rome, Italy
E: clinicalpediatrics@pediatricsconferences.org
W: clinicalpediatrics.conferenceseries.com

Advances in Neonatal and Pediatric Nutrition
July 19-21, 2018 London, UK
E: neonatalnutrition@annualconferences.org
W: pediatricnutrition.pediatricsconference.com

20th International Conference on
Pediatrics Primary Care
September 03-04 2018 Zurich, Switzerland
E: pediatricprimarycare@annualconferences.org
W: primarycare.pediatricsconferences.com

18th International Conference on
Pediatrics Health
August 06-07, 2018 Madrid, Spain
E: pediatricshealth@annualconferences.org
W: health.pediatricsconferences.com

24th European Pediatrics Conference
September 10-12, 2018 Copenhagen, Denmark
E: europediatrics@pediatricsconferences.org
W: pediatrics.conferenceseries.com/europe

24th World Pediatrics Conference
October 18-20, 2018 Warsaw, Poland
E: worldpediatrics@annualconferences.org
W: worldpediatrics.pediatricsconferences.org




26th International Conference on
Neonatology and Perinatology
November 15-17 2018 Edinburgh, Scotland
E: neonatology@pediatricsconferences.com
W: neonatology.conferenceseries.com

Petroleum





9th International Conference and Expo on
Oil and Gas
August 9-10, 2018 Madrid, Spain
E: petroleum@oilgasconferences.org
W: oil-gas.conferenceseries.com

Physical Therapy & Rehabilitation





5th International Conference and Expo on
Novel Physiotherapies
March 19-20, 2018 Berlin, Germany
E: novelphysiotherapies@annualconferences.org
W: novelphysiotherapies.conferenceseries.com

6th International Conference & Exhibition on
Physiotherapy & Physical Rehabilitation
August 13-14, 2018 London, UK
E: physiotherapy@annualconferences.org
W: physiotherapy.annualcongress.com

Pharma





12th World Congress on
Pharmaceutical Sciences and Innovations in Pharma Industry
February 26- 27, 2018 London, UK
E: pharmaindustry@pharmaceuticalconferences.org
W: industry.pharmaceuticalconferences.com




16th International Conference and Exhibition on
Pharmaceutics & Novel Drug Delivery Systems
March 19-21, 2018 Berlin, Germany
E: pharmaceutica@pharmaceuticalconferences.org
W: novel-drugdelivery-systems.pharmaceuticalconferences.com

11th European Biosimilars Congress
April 26-27, 2018 Rome, Italy
E: eurobiosimilars@pharmaceuticalconferences.org
W: biosimilars-biologics.pharmaceuticalconferences.com/europe

15th Annual European Pharma Congress
May 07-09, 2018 Frankfurt, Germany
E: pharmaeurope@pharmaceuticalconferences.org
W: europe.pharmaceuticalconferences.com

4th World Congress and Exhibition on
Antibiotics and Antibiotic Resistance
June 14-15, 2018 Barcelona, Spain
E: antibiotics@pharmaceuticalconferences.org
W: antibiotics.pharmaceuticalconferences.com

9th International Conference and Exhibition on
Pharmacovigilance
June 21-22, 2018 London, UK
E: pharmacovigilance@pharmaceuticalconferences.org
W: pharmacovigilance.pharmaceuticalconferences.com

4th International Conference and Exhibition on
Natural Products, Medicinal Plants & Marine Drugs
June 11-12, 2018 Rome, Italy
E: naturalproducts@pharmaceuticalconferences.org
W: naturalproducts.pharmaceuticalconferences.com

16th International Conference and Exhibition on
Pharmaceutical Formulations
July 26-27, 2018 Rome, Italy
E: formulations@pharmaceuticalconferences.org
W: formulation.pharmaceuticalconferences.com

10th World Congress on Pharmacology
July 30-Aug 01, 2018 Barcelona, Spain
E: pharmacology@pharmaceuticalconferences.org
W: pharmacology.pharmaceuticalconferences.com

4th International Conference and Expo on
Drug Discovery, Designing & Development
September 06-07, 2018 London, UK
E: drugdiscovery@pharmaceuticalconferences.org
W: drug-discovery.pharmaceuticalconferences.com

6th International Conference on
Advanced Clinical Research and Clinical Trials
September 10-11, 2018 Zurich, Switzerland
E: clinicalresearch@pharmaceuticalconferences.org
W: clinicalresearch.pharmaceuticalconferences.com

18th World Pharma Congress
October 18-19, 2018 Warsaw, Poland
E: pharmacongress@pharmaceuticalconferences.org
W: world.pharmaceuticalconferences.com


18th Annual Pharmaceutical and Chemical Analysis Congress
November 05-06, 2018 Madrid, Spain
E: analysis@pharmaceuticalconferences.org
W: analysis.pharmaceuticalconferences.com


3rd International Conference on
Generics Drugs and Biosimilars
November 15-17, 2018 Frankfurt, Germany
E: genericpharma@pharmaceuticalconferences.org
W: generic-market.pharmaceuticalconferences.com

9th Global Experts Meeting on
Neuropharmacology
November 15-16, 2018 Frankfurt, Germany
E: neuro@pharmaceuticalconferences.org
W: neuro.pharmaceuticalconferences.com

23rd International Conference on
Pharmaceutical Biotechnology
December 10-11, 2018 Rome, Italy
E: pharmabiotech@pharmaceuticalconferences.org
W: biotech.pharmaceuticalconferences.com

Physics



3rd International Conference on Nuclear and Plasma Physics
June 07-08, 2018 London, UK
E: plasmaphysics@annualconferences.org
W: plasmaphysics.physicsmeeting.com

5th International Conference on
Theoretical and Applied Physics
July 02-03, 2018 Vienna, Austria
E: appliedphysics@annualconferences.org
W: appliedphysics.physicsmeeting.com






9th International Conference on
Optics, Photonics & Lasers
July 02-04, 2018 Berlin, Germany
E: eurooptics@annualconferences.org
W: optics.physicsmeeting.com

4th International Conference on
Condensed Matter and Materials Physics
August 16-17, 2018 London, UK
E: materialsphysics@annualconferences.org
W: materialsphysics.physicsmeeting.com

3rd International Conference on
Quantum Optics and Quantum Computing
September 10-11, 2018 London, UK
E: quantumoptics@annualconferences.org
W: quantumoptics.physicsmeeting.com

4th International Conference on Physics
September 17-18, 2018 Berlin, Germany
E: physics@physicsconferences.org
W: physics.conferenceseries.com

4th International Conference on
Quantum Physics and Quantum Technology
October 18-19, 2018 Rome, Italy
E: quantumphysics@physicsconferences.org
W: quantumphysics.conferenceseries.com

3rd International Conference on
Astronomy and Space Science
October 18-19, 2018 Rome, Italy
E: astrospace@physicsconferences.org
W: astronomy-space.physicsmeeting.com

3rd International Conference on
Magnetism and Magnetic Materials
October 22-23, 2018 Rome, Italy
E: magneticmaterials@annualconferences.org
W: magneticmaterials.physicsmeeting.com

4th International Conference on
High Energy & Particle Physics
December 03-04, 2018 Valencia, Spain
E: highenergy@physicsconferences.org
W: highenergyphysics.conferenceseries.com

Psychiatry





4th International Conference on
Mental Health & Human Resilience
April 26-27, 2018 Rome, Italy
E: mentalhealth@conferenceseries.net
W: mentalhealth.conferenceseries.com

4th International Conference on
Depression, Anxiety and Stress Management
May 10-11, 2018 Frankfurt, Germany
E: stress@psychiatrycongress.com
W: stressmanagement.global-summit.com

27th World Congress on
Psychiatry & Psychological Syndromes
June 21-23, 2018 London, UK
E: psychiatrycongress.com

28th Euro Congress on
Psychiatrists and Psychologists
July 05-06, 2018 Vienna, Austria
E: europsychiatry@psychiatrycongress.com
W: psychiatry.global-summit.com/europe

29th International Conference on
Psychiatry & Psychology Health
July 09-10, 2018 Paris, France
E: psychologyhealth@annualconferences.org
W: psychologyhealth.conferenceseries.com

33rd International Conference on
Adolescent Medicine & Child Psychology
Sep 04-05, 2018 Zurich, Switzerland
E: childpsychology@conferenceseries.net
W: childpsychology.conferenceseries.com

3rd International Congress on
Forensic Science and Psychology
October 22-23, 2018 Athens, Greece
E: forensiccongress@psychiatrycongress.com
W: forensic.conferenceseries.com







35th International Conference on
Psychiatry & Psychosomatic Medicine
November 01-03, 2018 Brussels, Belgium
E: psychosomaticmedicine@psychiatrycongress.com
W: psychosomatic.conferenceseries.com

Surgery





3rd International Conference on
Metabolic and Bariatric Surgery
March 15-16, 2018 Barcelona, Spain
E: bariatricsurgery@annualconferences.org
W: bariatricsurgery.conferenceseries.com

7th International Conference and Exhibition on Surgery
June 21-23, 2018 Dublin, Ireland
E: surgery@surgeryconferences.org
W: sugery.conferenceseries.com

3rd International Conference on Anesthesia
June 21-22, 2018 Dublin, Ireland
E: anesthesia@annualconferences.org
W: anesthesia.conferenceseries.com

13th International Conference on
Arthroplasty and Orthopedics
August 08-09, 2018 Rome, Italy
E: arthroplasty@annualconferences.org
W: orthopedics.surgeryconferences.com

8th International Conference and Expo on
Cosmetology, Trichology & Aesthetic Practices
August 13-14, 2018 Madrid, Spain
E: cosmetologycongress@surgeryconferences.org
W: cosmetology.surgeryconferences.com

World Congress on
Neurology and Neuromuscular Disorders
September 13-14, 2018 Frankfurt, Germany
E: neuromuscular@annualconferences.org
W: neuromuscular.neuroconferences.com

3rd European Otolaryngology-ENT Surgery Conference
October 08-10, 2018 London, UK
E: ent@surgeryconferences.org
W: ent.conferenceseries.com

2nd International Conference on
Craniofacial Surgery
October 08-09, 2018 London, UK
E: craniofacial@annualconferences.org
W: craniofacial.surgeryconferences.com

9th European Congress of Rheumatology,
Autoimmunity and Orthopedics
October 16-17, 2018 Warsaw, Poland
E: rheumatology@annualconferences.org
W: rheumatology.conferenceseries.com

Toxicology





15th Euro-Global Summit on
Toxicology and Applied Pharmacology
July 02-04, 2018 Berlin, Germany
E: eurotoxicology@annualconferences.org
W: toxicology.global-summit.com/europe

16th Annual Meeting on
Environmental Toxicology and Life Sciences
August 13-14, 2018 London, UK
E: euroenvitox@annualconferences.org
W: environmentaltoxicology.toxicologyconferences.com

Vaccines





29th International Conference on
Vaccines and Immunization
March 19-20, 2018 London, UK
E: vaccinessummit@immunologyconferences.org
W: vaccines-immunization.conferenceseries.com

31st Euro Global Summit and Expo on
Vaccines & Vaccination
June 14-16, 2018 Barcelona, Spain
E: eurovaccines@vaccineconference.com
W: europe.vaccineconferences.com












4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Keynote Forum

Day 1

Laxminarayan Bhat, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-017



Laxminarayan Bhat

Reviva Pharmaceuticals, Inc., USA

Serotonergic targets in the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF)

Pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) are two progressive, debilitating, and fatal lung diseases. Both diseases are limited in treatment options and have no cure. Pulmonary hypertension, inflammation, and structural remodeling, all with varying degrees of severity, are the most common and significant underlying pathophysiologic factors associated with these conditions. Although the pathogenesis is not clearly understood, increased levels of inflammatory cytokines, including growth factors and dysfunctional endothelial vasoactive mediators (e.g., serotonin, 5-HT; endothelin, ET; nitric oxide, NO; and prostacyclin, PGI2), are found in the lungs of PAH and IPF patients. The 5-HT receptor signaling pathway appears to play a central role in the pathobiology of both conditions. RP5063, a new chemical entity, is a potent modulator of 5-HT signaling that involves specifically the 5-HT2A/2B/7 receptors within the lung. The signal transduction pathways involving these 5-HT receptors mediate significant underlying pathophysiology (vasoconstriction, and vascular/alveolar inflammation, fibrosis, and proliferation) for PAH and IPF. RP5063 has demonstrated proof of concept in translational animal models that emulate IPF and PAH in humans. The U.S. FDA has granted an Orphan Drug Designation to RP5063 for the treatment of PAH and IPF, in which clinical phase 2 studies are planned to start soon. This presentation will briefly review approved therapies and unmet medical needs for PAH and IPF. It will segue to the current understanding of 5-HT receptor signaling pathways in the pathobiology of these two diseases, and will then discuss RP5063 pharmacology and preclinical efficacy for PAH and IPF. It will close by delineating the clinical pharmacokinetic/pharmacodynamic and safety profiles of this compound.

Recent Publications

1. Bhat L, Hawkinson J, Cantillon M, et al. (2017). RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-induced pulmonary arterial hypertension in rats. European J Pharmacology, 810: 83-91.
2. Bhat L, Hawkinson J, Cantillon M, et al. (2017). RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. European J Pharmacology, 810: 92-99.
3. Cantillon M, Ings R,, and Bhat L. (2018) A population pharmacokinetic and pharmacodynamic analysis of phase 2 study data evaluating RP5063 in patients with schizophrenia or schizoaffective disorder. European Journal of Drug Metabolism and Pharmacokinetics, (00) 1-13.
4. Cantillon M, Ings R, Bhat L. (2018). RP5063 Phase 1 Experience: Evaluation of safety in normal healthy volunteers and of safety, and pharmacodynamics of multiple-doses over 10 days to stable schizophrenia patients. Clinical & Translational Science, (00) 1-10.

Biography

Laxminarayan Bhat, PhD, is the Founder, President, and Chief Executive Officer of Reviva Pharmaceuticals, Inc. Dr. Bhat founded Reviva in 2006 and since its inception, the company has advanced rapidly under his leadership with a portfolio of propriety compounds at different stages in a pipeline encompassing central nervous system (CNS), cardiovascular, and inflammatory diseases. Dr. Bhat has over 20 years of experience in drug discovery and development, and prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics, and Higuchi Biosciences Center in the United States. Dr. Bhat conducted extensive graduate and post-graduate training in medicinal chemistry in India, France, Germany, and USA. Dr. Bhat has published over 25 research papers in peer reviewed international journals and has given several invited lectures/presentations in national and international conferences. Dr. Bhat is an inventor with over 60 granted patents and contributed to one approved drug currently in the market worldwide.

Lbhat@revivapharma.com

Gianluca Colella, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-017



Gianluca Colella

Rizzoli Orthopaedic Institute, Italy

Surgical treatment of early onset scoliosis associated with rare disease

Background: Kyphoscoliosis is the most common and rapidly evolving spinal deformity in rare syndromes. Early Onset and Congenital deformities, often associated with a lot of malformation, are difficult to manage. The aim of the study is to describe an approach to spinal deformities in rare syndromes and assess the effectiveness of growing systems.

Methods: We report 11 cases of pediatric patients with scoliosis (7 males, 4 females) : 2 NF1, 2 arthrogryposis, 1 Spondylo-rib dysplasia, 1 trisomy 8, 1 syringomyelia, 1 Arnold Chiari type I, 1 Prader Willi, 1 Kabuki syndrome, 1 Escobar. This is a retrospective study from 2006 to 2011. The inclusion criteria were 1) EOS or congenital scoliosis in rare disease, 2) Growing rod system, 3) follow-up 24 months (12-36) . Surgery was performed using VEPTR in 4 patients (Mean age 1st visit: 3 yy (1-7) at surgery: 5 yy (3-9), GROWING ROD in 7 patient (Mean age 1st visit: 6 yy (3-10) at surgery: 9 yy (5-12).

Results: The patients were clinically and radiologically reviewed at a mean follow-up of 11 months. We made 11 first surgery and 15 lengthening procedures. The thoracic curve correction was of 50% (from 65° to 39°). Children are grown on average of 2,5 cm/ each follow up year, results so similar to the phisiological growth. We had 8 postoperative mechanical complications on 26 surgeries: 4 screws loosening, 3 broken rods, 1 rib-hook loosening; 6 cases were treated during the planned lenghthening and 2 with revision surgery not originally planned.

Conclusions: Our strategy is for each patient working in team, with other colleagues more specialist and a particular route starts from a dedicate ambulatory (Rare disease ambulatory). The first step is to be aware of the specific diagnosis of a suspected syndrome; without a confirmed genetic diagnosis of a suspected syndrome, it is impossible to plan preoperative strategy for major spine surgery to minimize the risk of increased morbidity and mortality due to the syndrome.The preoperative programs need a particular flow chart with all exams to study the case, such as X-Rays, MRI, Cardio and abdominal US, CT scan, anaesthesiologist, neurological, pneumological visits. The growing systems are good tools and effective in the treatment of early-onset scoliosis in rare syndromes. Early surgical treatment is needful for these deformities that don't respond at the conservative treatment. The correction rate depends on the age at first surgery and earlier we start better will be the results.

Biography

Gianluca Colella is specialized works in Orthopaedics and Traumatology at University Federico II – Napoli, Fellow at Spine Surgery Division - Istituto Ortopedico Rizzoli. He has done his Master Degree in Medicine and Surgery at University Federico II Naples, with a discussion "Trattamento chirurgico e tecniche ricostruttive dei tumori del femore prossimale: limb salvage surgery", and also Abilitation to Medical and Surgical Profession. . He is also responsible for a specialized clinic dedicated to the study and treatment of severe spinal deformities associated with rare diseases at the Rizzoli Orthopedic Institute.

glc.colella@gmail.com

Abdulaziz Aldawood, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-017



Abdulaziz Aldawood

King Saud Bin Abdulaziz University, Saudi Arabia

Clinical course and outcomes of critically ill patients with middle-east respiratory syndrome coronavirus infection

Background: Since September 2012, 170 confirmed infections with Middle East respiratory syndrome coronavirus (MERS-CoV) havebeen reported to the World Health Organization, including 72 deaths. Data on critically ill patients with MERS-CoV infection are limited.

Objective: To describe the critical illness associated with MERS-CoV.

Design: Case series.

Setting: 3 intensive care units (ICUs) at 2 tertiary care hospitals in

Saudi Arabia.

Patients: 12 patients with confirmed or probable MERS-CoV infection.

Measurements: Presenting symptoms, comorbid conditions, pulmonary and extrapulmonary manifestations, measures of severity of illness and organ failure, ICU course, and outcome are described, as are the results of surveillance of health care workers (HCWs) and patients with potential exposure.

Results: Between December 2012 and August 2013, 114 patients were tested for suspected MERS-CoV; of these, 11 ICU patients (10%) met the definition of confirmed or probable cases. Three of these patients were part of a health care–associated cluster that also included 3 HCWs. One HCW became critically ill and was the 12th patient in this case series. Median Acute Physiology and Chronic Health Evaluation II score was 28 (range, 16 to 36). All 12 patients had underlying comorbid conditions and presented with acute severe hypoxemic respiratory failure. Most patients (92%) had extrapulmonary manifestations, including shock, acute kidney injury, and thrombocytopenia. Five (42%) were alive at day 90. Of the 520 exposed HCWs, only 4 (1%) were positive.

Limitation: The sample size was small.

Conclusion: MERS-CoV causes severe acute hypoxemic respiratory failure and considerable extra pulmonary organ dysfunction and is associated with high mortality. Community-acquired and health care–associated MERS-CoV infection occurs in patients with chronic comorbid conditions. The health care–associated cluster suggests that human-to-human transmission does occur with unprotected exposure.

Biography

Deputy Chairman, Intensive Care Department, Consultant, Pulmonary and Critical Care Medicine, Professor, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia, Dr. AlDawood graduate from College of Medicine in Kingdom of Saudi Arabia. Then he completed the Residency in Internal Medicine Program in McMaster University in Canada He obtained Critical Care and Respirology Fellowship Program in McMaster University, Canada (Jul 97-Jun 00). In July 2000, he joined King Abdulaziz Medical City, Riyadh, Saudi Arabia as a Consultant in Critical Care and Pulmonary Medicine up to the present. He is currently the Deputy Chairman of the Intensive Care Department and Professor in King Saud Bin Abdulaziz University for Health Sciences. In addition, he has more than 40 publications including articles in the New England Journal of Medicine (NEJM), JAMA, American Journal of Respiratory Critical Care Medicine, BMC Anesthesiology, and Critical Care Medicine.

aldawooda@hotmail.com







4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Scientific Tracks & Abstracts

Day 1

Sessions:

Day 1 June 11, 2018

Rare Genetic Diseases | Pediatric Rare Diseases | Rare Hereditary Diseases | Diagnosis and Treatment for Rare Diseases | Clinical case studies on Rare Diseases

Session Chair
Karren Williams
Akcea Therapeutics, USA

Session Chair
Alan Gilstrap
Akcea Therapeutics, USA

Session Introduction

Title: Rare diagnosis in disorders/differences of sex development
Yolande van Bever, Erasmus Medical Centre, The Netherlands

Title: Evaluating the impact of peer support and connection on the quality of life of patients with familial Chylomicronemia Syndrome
Alan Gilstrap, Akcea Therapeutics, USA

Title: Pulmonary arterial hypertension and pulmonary fibrosis: Treatments, unmet needs, and future directions
Laxminarayan Bhat, Reviva Pharmaceuticals, Inc, USA

Title: Synthetic messenger RNA-based therapeutic strategy for treatment of alpha-1-antitrypsin deficiency
Tatjana Michel, University Hospital Tuebingen, Germany

Title: Surgical treatment of scoliosis in rare diseases: Arthogryposis
Gianluca Colella, Rizzoli Orthopaedic Institute, Italy

Title: Rare diseases in Kuwait: The experience of Genatak Center for Genomic Medicine
Fahd Al Mulla, Kuwait University, Kuwait

Yolande van Bever, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Rare diagnosis in disorders/differences of sex development

Yolande van Bever
Erasmus Medical Centre, The Netherlands

DSD (Disorders/Differences of Sex Development) comprise a rare group of diseases and abnormalities that can present on different ages and have very variable presenting symptoms. Prenatally discrepancy between genotypic sex and ultrasound phenotype or an abnormal genital as seen by ultrasound. Neonatal or pediatric symptoms can be a genuine ambiguous genital, inguinal (ovotestes) in a girl detected during inguinal hernia surgery, small stature in a 45,X/46 XY girl etc. Others are only detected at puberty or when trying to get pregnant.There is consensus that patients should be evaluated by multidisciplinary teams and that it is important to involve patients or caretakers in the process of diagnosis and management. Psychological, socio-cultural and economic-organizational aspects play an important role.Within the group of diagnosis that fall under the term DSD, there are well-known syndromes as Turner syndrome and variants, CAH, or proximal hypospadias, which can have many causes and can present as ambiguous genitalia. Other causes are very rare and may not be easily recognized. Some of these will be presented here. The experience and organization of our team and DSD care in the Netherlands and the place and timing of NGS based diagnostics will be discussed. For the future it is important to realize the importance of choosing the right words to communicate about the condition, especially also for professionals who have little or no experience with DSD but who are frequently the first to see the patient. Transition from prenatal care to postnatal professionals, from a peripheral clinic to a specialized clinic or from adolescent to adult specialists often offers room for improvement. We should not neglect that in these exciting times of growing diagnostic possibilities.

Recent Publications

1. Van Bever Y, Wolffenbuttel KP, Brüggenwirth HT, Blom E, de Klein A, Eussen BHJ, van der Windt F, Hannema SE, Dessens AB, Dorssers LCJ, Biermann K, Hersmus R, de Rijke YB, Looijenga LHJ. Multiparameter Investigation of a 46,XX/46,XY Tetragametic Chimeric Phenotypical Male Patient with Bilateral Scrotal Ovotestes and Ovulatory Activity. Sex Dev. 2018;12(1-3):145-154.

2. Hersmus R, van Bever Y, Wolffenbuttel KP, Biermann K, Cools M, Looijenga LH. The biology of germ cell tumors in disorders of sex development. Clin Genet. 2017 Feb;91(2):292-301.

3. Brosens E, Marsch F, de Jong EM, Zaveri HP, Hilger AC, Choinitzki VG, Hölscher A, Hoffmann P, Herms S, Boemers TM, Ure BM, Lacher M, Ludwig M, Eussen BH, van der Helm RM, Douben H, Van Opstal D, Wijnen RM, Beverloo HB, van Bever Y, Brooks AS, IJsselstijn H, Scott DA, Schumacher J, Tibboel D, Reutter H, de Klein A. Copy number variations in 375 patients with oesophageal atresia and/or tracheoesophageal fistula. Eur J Hum Genet. 2016 Dec;24(12):1715-1723.

4. Halim D, Hofstra RM, Signorile L, Verdijk RM, van der Werf CS, Sribudiani Y, Brouwer RW, van IJcken WF, Dahl N, Verheij JB, Baumann C, Kerner J, van Bever Y, Galjart N, Wijnen RM, Tibboel D, Burns AJ, Muller F, Brooks AS, Alves MM. ACTG2 variants impair actin polymerization in sporadic Megacystis Microcolon Intestinal Hypoperistalsis Syndrome. Hum Mol Genet. 2016 Feb 1;25(3):571-83.

5. van den Hondel D, Wijers CH, van Bever Y, de Klein A, Marcelis CL, de Blaauw I, Sloots CE, IJsselstijn H. Patients with anorectal malformation and upper limb anomalies: genetic evaluation is warranted. Eur J Pediatr. 2016 Apr;175(4):489-97.

Biography

Yolande van Bever is a clinical geneticist with expertise in congenital anomalies and syndromes and with a special interest in the field of DSD. She worked in various academic hospitals in the Netherlands and abroad. Since 2004 she is an active team member not only in the clinical genetic staf, but also in various multidisciplinary teams such as the follow up team on surgical congenital anomalies, the neurofibromatosis team and the DSD team. In view of the rapid growing diagnostic genetic possibilities it is important to focus on communication with patients and their caretakers. .

y.vanbever@erasmusmc.nl

Gilstrap A et al., J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Evaluating the impact of peer support and connection on the quality of life of patients with familial chylomicronemia syndrome (FCS)

Gilstrap A[1], Salvatore V[1], Williams K[1], Hsieh A[1], Gwosdow AR[2], Stevenson M[1], Davidson D[3]
[1]AkceaTM Therapeutics, USA
[2]Gwosdow Associates Science Consultants, LLC, USA
[3]NorthShore University Health System, USA

Synopsis: FCS is a rare genetic disease characterized by extreme hypertriglyceridemia due to high chylomicron accumulation in the plasma. Burden of illness previously reported in the InFOCUS study, showed patients with FCS report psychosocial symptoms including anxiety, fear/worry, cognitive impairment, and physical symptoms including fatigue, abdominal pain, acute and recurrent pancreatitis. Community support and mentorship, either in-person interactions or online patient/caregiver forums, play an important role in helping patients manage their rare disease needs and associated psychosocial challenges. There is little current research assessing the impact of being connected to FCS-specific networks on the quality of life (QoL) in patients with FCS.

Objective: Assess the possible impact of connections and patient/caregiver engagement with patient advocacy groups and social media platforms on QoL of patients with FCS.

Methods: A web-based survey was designed to assess the level of social connectedness for patients/caregivers. Participants identified as having FCS or caregivers for FCS patients, were classified as being 'actively' (participating ≥once every 2wks) or 'passively' (participating <once every 2wks/never) connected with FCS-specific networks. Study was approved by the Institutional Review Board and relevant ethics committees.

Results: Preliminary data, from limited participants (n=10), indicate that 70% of respondents were actively connected to peers via FCS-specific networks. Time spent connected to various networks ranged from 7.8-24 months. Respondents reported better overall health after being connected to FCS-specific networks. Patients reported improvements in mental, emotional/psychosocial symptoms related to FCS after being connected. Early data from connected patients showed a trend towards improved social relationships, and higher QoL satisfaction. Evidence from preliminary data indicates respondents show a trend towards reduction in perception of FCS severity.

Conclusion: Preliminary self-reported data indicates support/connection through FCS-specific networks show a positive-trend in improving overall health and social relationships, and reducing anxiety levels and depression in patients with FCS and their caregivers.

Recent Publications

1. Davidson, M., et al. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. *Expert Review of Cardiovascular Therapy.* Mar 2017.
2. Gelrud, A., et al. The burden of familia chylomicronemia syndrome form the patients' perspective. *Expert Review of Cardiovascular Therapy.* Sept 2017.
3. Ahmad, Z., et al. Building a better understanding of the burden of disease in familial chylomicronemia syndrome. *Expert Review of Clinical Pharmacology*. Nov 2016.

Biography

Dr.Alan Gilstrap has experience in the pharmaceutical industry with previous leadership roles at Akcea Therapeutics. He was intricately involved in the design and refinement of the study survey as well as being largely responsible for study approval and access in the United States and Canada.

bhubbard@akceatx.com

Laxminarayan Bhat, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Pulmonary arterial hypertension and pulmonary fibrosis: Treatments, unmet needs, and future directions

Laxminarayan Bhat
Reviva Pharmaceuticals, Inc., USA

Pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) are two progressive, debilitating, and fatal lung diseases. Both conditions are limited in their treatment options and have no cure. They share some common underlying pathophysiologic features with varying degrees of severity. The major ones include pulmonary hypertension, inflammation, and structural remodeling. Developing pharmacological treatments for these lung diseases is a challenging task as the pathogenesis is not clearly understood. There are three classes of drugs widely used often in combinations for the treatment of PAH: (1) phosphodiesterase 5 (PDE-5) inhibitors; (2) endothelin receptor antagonists; and (3) prostanoids. These drugs are pulmonary vasodilators and do not reverse the structural changes in the pulmonary vascular bed. Therefore, the current treatments are not effective in preventing or delaying the progression of PAH. Similarly, there are two drugs (nintedanib and pirfenidone) approved for the treatment of IPF. They are not effective in significantly delaying the progression of this condition. Also, the majority of these lung disease patients suffer from chronic mental and metabolic comorbidities. The average lifespan of patients after diagnosis for PAH is 5-7 years and for IPF 3 years. Thus, there is a significant unmet medical need and growing demand to develop novel treatments that can significantly delay the disease progression, if not to provide a cure, and to improve patient quality of life. This presentation will briefly review current understanding of the pathobiology of PAH and IPF, approved therapies, unmet medical needs, and novel treatments in development in the industry. This discussion will examine some the translational challenges involved in the development of new therapeutic options and the lessons learned. Finally, it will close by (1) delineating the concerns related to intellectual properties and commercialization and (2) by providing insight into future directions in the management of these conditions.

Biography

Laxminarayan Bhat, Ph.D., is the Founder, President, and Chief Executive Officer of Reviva Pharmaceuticals, Inc. Dr. Bhat founded Reviva in 2006, and since its inception, the company has advanced rapidly under his leadership with a portfolio of propriety compounds at different stages in a pipeline encompassing central nervous system (CNS), cardiovascular, and inflammatory diseases. Dr. Bhat has over 20 years of experience in drug discovery and development. Prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics, and Higuchi Biosciences Center in the United States. Dr. Bhat conducted extensive graduate and post-graduate training in medicinal chemistry in India, France, Germany, and the USA. Dr. Bhat has published over 25 research papers in peer-reviewed international journals. He has given several invited lectures/presentations at national and international conferences. Dr. Bhat is an inventor with over 60 granted patents and contributed to one approved drug currently in the market worldwide.

Lbhat@revivapharma.com

Notes:

Tatjana Michel, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Synthetic messenger RNA-based therapeutic strategy for treatment of alpha-1-antitrypsin deficiency

Tatjana Michel
University Hospital Tuebingen, Germany

Alpha-1-antitrypsin deficiency (AATD) is one of the most common monogenic diseases worldwide. A mutation in alpha-1-antitrypsin (AAT) protein causes the protein to misfold and accumulate in hepatocytes instead of being secreted into the blood stream. This deprives the lungs from AAT protein, which plays a protective role against neutrophil elastase proteolytic activity. Both the accumulation in the hepatocytes and absence from lung lead to permanent irreversible tissue damage in the form of cirrhosis and pulmonary emphysema. Currently, AATD patients receive an AAT protein replacement therapy but it comes at undesirable side effects and high costs. In addition, gene therapy approaches are tested in clinical trials but with serious immunogenic, mutagenic and carcinogenic consequences. Therefore, a novel therapeutic strategy based on messenger RNA (mRNA) was established, which can be used to achieve a targeted and controllable induction of AAT expression in target cells. First, an AAT-encoding mRNA was generated and tested *in vitro*. Here, it could be shown that the AAT mRNA is translated into a bioactive protein capable of efficiently inhibiting neutrophil elastase. Furthermore, the encapsulation of mRNA into nanoliposomes was optimized for later *in vivo* use. These nanoliposomes were prepared from a cationic and a neutral lipid and analyzed for mRNA encapsulation capacity, transfection efficiency, immunogenicity, biocompatibility and hemocompatibility. Compared to Lipofectamine 2000, a significantly higher translation of the AAT protein was detected during the *in vitro* experiments using prepared nanoliposomes. In addition, after incubation with the liposomes, cells showed no adverse effects on viability and no upregulation of innate immune defense genes. Furthermore, no negative effects could be observed in the form of complement system, leukocyte and platelet activation. This work lays the foundation for comprehensive mRNA-based therapeutic strategy for AATD patients and could serve as an alternative to protein replacement therapy and gene therapy in clinical use.

Recent Publications

1. T Michel, D Luft, M-K Abraham, S Reinhardt, M L. Salinas Medina, J Kurz, M Schaller, M Avci-Adali, C Schlensak, K Peter, H P Wendel, X Wang, S Krajewski (2017) Nanoliposomes meet mRNA: Efficient delivery of modified mRNA using hemocompatible and stable vectors for therapeutic applications, Molecular Therapy – Nucleic Acids
2. Abraham MK, Peter K, Michel T, Wendel HP, Krajewski S, Wang X (2017) Nanoliposomes for Safe and Efficient Therapeutic mRNA Delivery: A Step Toward Nanotheranostics in Inflammatory and Cardiovascular Diseases as well as Cancer, Nanotheranostics
3. Tatjana Michel, Hans-Peter Wendel and Stefanie Krajewski (2016) Next-Generation Therapeutics: mRNA as a Novel Therapeutic Option for Single-Gene Disorders, Book: Modern Tools for Genetic Engineering, InTech
4. Michel T, Kankura A, Salinas Medina ML, Kurz J, Behring A, Avci-Adali M, Nolte A, Schlensak C, Wendel HP, Krajewski S (2015) *In Vitro* Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency, Nucleic Acid Therapeutics
5. Avci-Adali M, Hann L, Michel T, Steinle H, Stoppelkamp S, Stang K, Narita M, Schlensak C, Wendel HP (2015) *In vitro* test system for evaluation of immune activation potential of new single-stranded DNA-based therapeutics, Drug Testing and Analysis
6. Avci-Adali M, Steinle H, Michel T, Schlensak C, Wendel HP (2013) Potential capacity of aptamers to trigger immune activation in human blood, PLoS one.

Biography

Tatjana Michel works with synthetic modified mRNA treatment strategy since 2013. Her work is focused on the development and evaluation of mRNA-based drugs for rare monogenetic diseases like alpha-1-antitrypsin deficiency or familial hypercholesterolemia. Prior to that, she worked on strategies for cell transdifferentiation for heart regeneration and investigated immunogenic effects caused through synthetic nucleic acids.

tatjana.michel@uni-tuebingen.de

Gianluca Colella et al., J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Surgical treatment of scoliosis in rare diseases: Arthogryposis

Gianluca Colella, Tiziana Greggi, Konstantinos Martikos and **Francesco Vommaro**
Rizzoli Orthopaedic Institute, Italy

Background: The reported incidence of scoliosis in arthrogryposis varies from 30% to 67% and, in most cases, the curves progress rapidly and become stiff from early age. The authors report six cases of scoliosis in arthrogryposis to assess the role of surgical treatment.

Methods: Six cases (3 males, 3 females; mean age at surgery 13.2 years) with arthrogryposis multiplex congenital associated with the characteristic amyoplasia were reviewed: they were operated on for scoliosis at the authors' Spine Surgery Department between 1987 and 2008. Surgery was performed using the Harrington-Luque instrumentation (2 cases), the Luque system (1), a hybrid segmental technique with hooks and screws (1) and spinal anchoring with pedicle screws (2).

Results: The patients were clinically and radiologically reviewed at a mean follow-up of 4.2 years, ± 2.7 (range, 1 to 9 years). Three minor postoperative complications were encountered; a long-term pulmonary complication was seen in one case after reintervention and was successfully resolved after 10 days. Surgery was successful in the other 5 cases, where solid arthrodesis was achieved and no significant curve progression was observed at followup.

Conclusions: The experience acquired with the present case series leads the authors to assert that prompt action should be taken when treating such aggressive forms of scoliosis. In case of mild spinal deformities in arthrogryposis, brace treatment should be attempted, the evolution of the curves being unpredictable; however, when the curve exceeds 40° and presents with marked hyperkyphosis, hyperlordosis or pelvic obliquity, surgery should not be delayed.

Biography

Gianluca Colella is specialized works in Orthopaedics and Traumatology at University Federico II – Napoli, Fellow at Spine Surgery Division - Istituto Ortopedico Rizzoli. He has done his Master Degree in Medicine and Surgery at University Federico II Naples, with a discussion "Trattamento chirurgico e tecniche ricostruttive dei tumori del femore prossimale: limb salvage surgery", and also Abilitation to Medical and Surgical Profession. . He is also responsible for a specialized clinic dedicated to the study and treatment of severe spinal deformities associated with rare diseases at the Rizzoli Orthopedic Institute.

glc.colella@gmail.com

Notes:







4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Scientific Tracks & Abstracts

Day 2

Rare Diseases Congress-2018

Sessions:

Day 2 June 12, 2018

Current Rare Diseases Research | Orphan Drugs Market Research | Rare Diseases of Sexual Health | Scope of Orphan Drugs | Rare Diseases in Neurology

Session Chair
Karren Williams
Akcea Therapeutics, USA

Session Chair
Alan Gilstrap
Akcea Therapeutics, USA

Session Introduction

Title: Results of the investigation of findings and observations captured in burden of illness survey in FCS patients (in-focus) study: European respondents
Karren Williams, Akcea Therapeutics, USA

Title: Hepatitis c virus testing and treatment among persons receiving buprenorphine in an office -based program for opioid use disorders in Nigeria
Samuel Ayoola Abati, lagos university, Nigeria

Title: Synthetic messenger RNA (mRNA) as a therapeutic tool
Tatjana Michel, University Hospital Tuebingen, Germany

Title: Rare diseases in west Africa
Ndiaye Mady, Faculty of Medicine of Thiès, Nigeria

Williams KR et al., J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Results of the investigation of findings and observations captured in burden of illness survey in FCS patients (in-focus) study: European respondents

Williams KR[1], Davidson M[1], Stevenson M[2], Hsieh A[2], Jones R[2], Issa B[3], Romeo S[4]
[1]Akcea Therapeutics™, Inc., USA;
[2]Department of Medicine, University of Chicago, USA
[3]Department of Endocrinology, University Hospital of South Manchester, UK
[4]University of Gothenburg, Sahlgrenska Academy & Sahlgrenska University Hospital, Department of Cardiology, Sweden

Introduction: Familial Chylomicronemia Syndrome (FCS), is a rare autosomal recessive disease characterized by extremely high serum triglycerides (TGs), carried in chylomicrons, which predisposes the patient to recurrent episodes of abdominal pain and risk of acute pancreatitis (AP). The physical, emotional, psychosocial and cognitive consequences of living with FCS are poorly understood and not documented in the literature.

Methods: The In-FOCUS web-based patient survey was undertaken to quantify the burden of illness and quality of life from the patient's perspective.

Results: 14 adult FCS patients from 5 European countries completed the survey. The majority of patients (64.3%) reported that their disease adversely affected their life over the past 12 months; with their stress/anxiety level (64.3%), ability to socialize (57.1%), ability to travel for work or leisure (57.1%), their mental ability (53.8%), quality of sleep (50.0%), and their feeling of self-worth (50.0%) all impacted. Over the past 12 months, 42.9% of patients had to take an average of 10.8 days off work because of problems related to FCS. 58.3% of patients felt their disease had influenced their decision on whether to have children, or how many children to have. 57.1% of patients reported feeling a burden to those around them because of their FCS.

Conclusions: FCS imparts a marked burden to the patient which extends beyond the recognized physical symptoms.

Recent Publications:

1. Davidson, M., et al. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. *Expert Review of Cardiovascular Therapy*. Mar 2017.
2. Gelrud, A., et al. The burden of familia chylomicronemia syndrome form the patients' perspective. *Expert Review of Cardiovascular Therapy*. Sept 2017.
3. Ahmad, Z., et al. Building a better understanding of the burden of disease in familial chylomicronemia syndrome. *Expert Review of Clinical Pharmacology*. Nov 2016.

Biography

Dr.Karren Williams has experience in the pharmaceutical industry with previous leadership roles at Akcea Therapeutics. She was intricately involved in the design and refinement of the study survey as well as being largely responsible for study approval and access in the United States and Canada. Previously, she was also heavily involved in the largest global patient voice quality of life study in patients with FCS conducted by Akcea Therapeutics (IN-FOCUS).

bhubbard@akceatx.com

Samuel Ayoola Abati, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Hepatitis c virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders in Nigeria

Samuel Ayoola Abati
Lagos university teaching hospital, Nigeria

Aims: In nigeria, hepatitis c virus (hcv) infection is primarily spread through injection drug use. There is an urgent need to improve access to care for hcv among persons with opioid use disorders who inject drugs. The purpose of our study was to determine the prevalence of hcv, patient characteristics, and receipt of appropriate care in a sample of patients treated with buprenorphine for their opioid use disorders in a primary care setting.

Methods: This study used retrospective clinical data from the electronic medical record. The study population included patients receiving buprenorphine in the office based opioid treatment (obot) clinic within the adult primary medicine clinic at lagos medical center between october 2008 and august 2015 who received a conclusive hcv antibody ab test within a year of clinic entry. We compared characteristics by hcv serostatus using pearson's chi-square and provided numbers/percentages receiving appropriate care.

Results: The sample comprised 300 patients. Slightly less than half of all patients (n = 134, 27.7%) were hcv ab positive, and were significantly more likely to be older hausas and yoruba's, have diagnoses of post- traumatic stress disorder (ptsd) and bipolar disorder, have prior heroin or cocaine use, and be hi v- infected. Among the 134 hcv ab positive patients, 126 (67.7%) had detectable hcv ribonucleic acid (rna) Indicating chronic hcv infection; only 8 patients (2.21%) with chronic hcv infection ever initiated treatment.

Conclusion: Nearly half of patients (47.7%) receiving office-based treatment with Buprenorphine for their opioid use disorder had a positive hepatitis c virus antibody screening test, although initiation of hcv treatment was nearly non-existent (2.21%).

Biography

Samuel Ayoola Abati working as a researcher in lagos University, and has published many articles and publications and also gained experience and worked as a faculty of Infectious Diseases in Nigeria.

ayoabati@yahoo.com

Notes:

Tatjana Michel, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Synthetic messenger RNA (MRNA) as a therapeutic tool

Tatjana Michel
University Hospital Tuebingen, Germany

Disorders caused by missing or defective protein synthesis can lead to early-onset complications and the patients need a life-long treatment. Today, treatment options are often limited or ineffective and associated with high costs. Here, the *in vitro* transcribed (IVT) mRNA can be used as a potential drug. Synthetic mRNA has several advantages over conventional gene therapy and protein substitution strategies. The mRNA-based therapy is founded on the induction of the transient translation with the cell own ribosomes of fully functional proteins without integration into host genome. This approach minimizes the risk of mutagen and carcinogen effects. The control of translation duration as well as immunogenicity of mRNA can be achieved though different modifications and provide for different therapeutically applications, like replace or supplement proteins. Moreover, mRNA cocktails contacting mRNAs encodes for different proteins can be applied to induce the expression of different proteins simultaneously in one cell. The use of mRNA to develop therapeutic drugs opens up new perspectives and challenges in disease treatment.

Recent Publications:

1. T Michel, D Luft, M-K Abraham, S Reinhardt, M L. Salinas Medina, J Kurz, M Schaller, M Avci-Adali, C Schlensak, K Peter, H P Wendel, X Wang, S Krajewski (2017) Nanoliposomes meet mRNA: Efficient delivery of modified mRNA using hemocompatible and stable vectors for therapeutic applications, Molecular Therapy – Nucleic Acids
2. Abraham MK, Peter K, Michel T, Wendel HP, Krajewski S, Wang X (2017) Nanoliposomes for Safe and Efficient Therapeutic mRNA Delivery: A Step Toward Nanotheranostics in Inflammatory and Cardiovascular Diseases as well as Cancer, Nanotheranostics
3. Tatjana Michel, Hans-Peter Wendel and Stefanie Krajewski (2016) Next-Generation Therapeutics: mRNA as a Novel Therapeutic Option for Single-Gene Disorders, Book: Modern Tools for Genetic Engineering, InTech
4. Michel T, Kankura A, Salinas Medina ML, Kurz J, Behring A, Avci-Adali M, Nolte A, Schlensak C, Wendel HP, Krajewski S (2015) *In Vitro* Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency, Nucleic Acid Therapeutics
5. Avci-Adali M, Hann L, Michel T, Steinle H, Stoppelkamp S, Stang K, Narita M, Schlensak C, Wendel HP (2015) *In vitro* test system for evaluation of immune activation potential of new single-stranded DNA-based therapeutics, Drug Testing and Analysis
6. Avci-Adali M, Steinle H, Michel T, Schlensak C, Wendel HP (2013) Potential capacity of aptamers to trigger immune activation in human blood, PLoS one.

Biography

Tatjana Michel works with synthetic modified mRNA treatment strategy since 2013. Her work is focused on the development and evaluation of mRNA-based drugs for rare monogenetic diseases like alpha-1-antitrypsin deficiency or familial hypercholesterolemia. Prior to that, she worked on strategies for cell trans differentiation for heart regeneration and investigated immunogenic effects caused through synthetic nucleic acids.

tatjana.michel@uni-tuebingen.de

Mady Ndiaye et al., J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-018

Rare diseases in west Africa

Mady Ndiaye, Oumar Faye, Mamadou Lamine Djiba and **Massamba Sylla**
Faculty of Medicine of Thiès, Nigeria

These last ten years, we have been worked on some rare diseases in West Africa namely we talk about diseases transmitted by viruses like Zika, Dengue and Ebola but also de bacteria which are responsible for diseases like Lyme disease and Anaplamosis. We developed a one-step RT-PCR assay to detect ZIKV in human serum. In 2009 we demonstrated that Aedes aegypti, the "yellow fever mosquito", is the primary vector to humans of the four serotypes of dengue viruses (DENV1-4) and yellow fever virus (YFV) .In 2014, we studied the role of bacteria belonging to Anaplasmataceae family as the causes of acute illnesses of sheep in West Africa. We examined and sampled 120 febrile sheep in two regions of Senegal. The DNA extracted from these blood samples was tested by PCR using two pairs of primers (groEL-based and 16S rRNA gene-based). For the first time, A. phagocytophilum was found in sub-Saharan Africa. In 2015, we discussed the dissemination of filo viruses circulating within their possible chiropteran reservoir species. We reviewed that Vertebrate hosts suspected in the maintenance/transmission cycles and discussed their bio ecological features. We have been shown that despite the importance of the findings about reservoirs' discovery of ebola virus, several other questions such as plurispecific associations, migration routes, breeding cycles need to be addressed and are pointed, in order to generate risk maps for filoviruses' (re)emergence in West Africa.

Biography

Dr. Mady Ndiaye is the Professor-researcher of Genetics at the Faculty of Medicine of Thiès (Senegal). He is also responsible for the lectures, directed and practical in Cellular Biology, Molecular and Genetics in first year of SVT since 1997 at the Faculty of Sciences and Techniques of UCAD (Senegal) and also worked as a Professor-researcher in Cell Biology, Histology, Embryology and Genetics at the Private University "El Hadji Ibrahima Niass" "School of Medicine St Christopher-Iba Mar Diop".

mydya2001@yahoo.fr

Notes:







4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Posters

Duaa Mohammadat, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Adherence to antimycetomal medications and factors that may affect it

Duaa Mohammadat
University of Khartoum faculty of Medicine, Sudan

Mycetoma the flesh eating devastating disease, regarded as a common health problem in tropical and subtropical regions with many serious medical and socioeconomic impacts on patients and communities. So this study about adherence to medication effects, and poor medication adherence contribution to the prognosis and severity of the disease, General Objectives is to assess the adherence, to assess the practice of the adherence, and to determine the factors that affects the adherence. I conducted my study among 200 patients diagnosed with Mycetoma using the validated four items Morisky scale ,interviewing patients , at MRC ,Soba university hospital , Almost half of the patients has poor adherence to medications, feeling good and side effects of the drugs all affect adherence of the patients, also the regular follow up missing affect the patients compliance. There is a massive knowledge gap in the epidemiology, pathogenesis and management of mycetoma which has severely affected patients' management and proper planning for mycetoma prevention and control measurements.

Biography

Duaa is final medical student ,at the age of 22 years from Khartoum University , she was interrested about mycetoma as oneof the neglected disease , and her country Sudan is within Mycetoma Belt so she focus her reserch project in this issue , also Duaa Mohammadat is one of the members of organization which support Mycetoma patients called MPFA , also sheis member of PSO which concern about supporting needy pts. In general , now Duaa is working on her paper.

duaa.mohammadat@gmail.com

Yuqing shi, J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Large-single scale mitochondrial DNA deletions in different tissues of patients with Kearns-Sayre syndrome

Yuqing shi,
Beijing Children's Hospital, China

Objective: To investigate the clinical significance of samples except skeletal muscle that could be detected the large-scale single deletions directly in the diagnosis of Kearns-Sayre syndrome by concluding the clinical and genetic features of KSS.

Methods: The clinical data of four patients with KSS, which were diagnosed from 2016 to 2017 by Beijing Children's Hospital, Capital Medical University, were collected. The clinical features and gene mutation characteristics were analyzed retrospectively.

Results: 4 patients were all consistent with the diagnosis criteria of KSS, the age of onset was 8.2 years old on average (5.0-11.8), and the initial symptoms were no specificity. The common symptoms of the four cases were exercise intolerance, short statue, ophthalmoplegia, hypotonia, muscle weakness; cerebrospinal fluid protein concentration over 1000mg/L, the cerebral MRI showed that abnormal signals in the brainstem, in addition, white matter, thalamus, basal ganglia, cerebrum and cerebellum atrophy could be found. Moreover, three cases for cardiac conduction block, two for suspicious family history. Molecular analysis of the four cases revealed that the large-scale single deletions of mitochondrial DNA from the peripheral blood, the urine and other samples (muscle tissue, CSF, etc.) through the next-generation sequencing. Two cases for homogeneous variation. Of three cases who did pedigree analysis, only the mom of case 4 was detected the same variation with the proband.

Conclusions: With the development of the next-generation sequencing, the diagnosis of Kearns-Sayre syndrome was no longer than depending on the muscle biopsy. It is indeed possible to detect the large-scale single deletions in peripheral blood, urine and other samples, to improve the molecular diagnosis of KSS, which will have a significant influence on the diagnosis and management of KSS, but more cases will be needed in the future.

Recent Publications:

1. Zhu C C, Traboulsi E I, Parikh S. Ophthalmological findings in 74 patients with mitochondrial disease[J]. Ophthalmic Genet, 2017,38(1):67-69.
2. Yu M, Zhang Z, Wang Q Q, et al. Clinical and Brain Magnetic Resonance Imaging Features in a Cohort of Chinese Patients with Kearns-Sayre Syndrome[J]. Chin Med J (Engl), 2016,129(12):1419-1424.
3. Kwon W J, Bang S U, Oh S C, et al. Peripheral Nerve Block is Safely Administered in a Patient with Kearns-Sayre Syndrome[J]. Chin Med J (Engl), 2016,129(10):1251-1252.
4. Kabunga P, Lau A K, Phan K, et al. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy[J]. Int J Cardiol, 2015,181:303-310.
5. Kozak I, Oystreck D T, Abu-Amero K K, et al. NEW OBSERVATIONS REGARDING THE RETINOPATHY OF GENETICALLY CONFIRMED KEARNS-SAYRE SYNDROME[J]. Retin Cases Brief Rep, 2016.
6. Finsterer J, Zarrouk-Mahjoub S. Diagnosing Kearns-Sayre Syndrome Requires Genetic Confirmation[J]. Chin Med J (Engl), 2016,129(18):2267-2268.
7. Broomfield A, Sweeney M G, Woodward C E, et al. Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease[J]. J Inherit Metab Dis, 2015,38(3):445-457.

Biography

Yuqing shi is a master student major in children neurology of professor FangFang, Beijing Children's Hospital, who has her expertise in evaluation and passion in improving the life quality of the patients and their families with mitochondrial diseases.

jlldbbt@163.com







4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Accepted Abstracts

Rare Diseases Congress-2018

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Paracrine action of human mesenchymal stem cells for muscle diseases

Jong Wook Chang
Samsung Medical Center, South Korea

The role of Wharton's jelly-derived human mesenchymal stem cells (WJ-MSCs) in inhibiting muscle cell death has been elucidated in the present study. Apoptosis induced by serum-deprivation in mouse myoblast cell lines (C2C12) was significantly reduced when the cell lines were co-cultured with WJ-MSCs in a transwell system. Antibody arrays indicated high levels of chemokine (C motif) ligand (XCL1) secretion by co-cultured WJ-MSCs and XCL1 protein treatment resulted in complete inhibition of apoptosis in serum-starved C2C12 cells. Apoptosis of C2C12 cells and loss of differentiated C2C12 myotubes induced by lovastatin, another muscle cell death inducer, was also inhibited by XCL1 treatment. However, XCL1 treatment did not inhibit apoptosis of cell lines other than C2C12. When XCL1-siRNA pretreated WJ-MSCs were co-cultured with serum-starved C2C12 cells, apoptosis was not inhibited, thus confirming that XCL1 is a key factor in preventing C2C12 cell apoptosis. We demonstrated the therapeutic effect of XCL1 on the zebrafish myopathy model, generated by knock down of a causative gene ADSSL1 encoding a muscle isozyme of adenylosuccinate synthase. The exogenous expression of XCL1 resulted in significant recovery of the zebrafish skeletal muscle defects. These results suggest that human WJ-MSCs and XCL1 protein may act as pro-mixing and novel therapeutic agents for treatment of myopathies and other skeletal muscle diseases.

jongwook.chang@samsung.com

conferenceseries.com

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

4th World Congress on

Rare Diseases and Orphan Drugs

June 11-12, 2018 | Dublin, Ireland

Hereditary spastic paraplegias phenotype constitute part of broader rare genetic Mendelian inherited disorders

Alice Abdel Aleem[1], Mahmoud F Elsaid[2], Nader Chalhoub[1], Khalid Ibrahim[2], MajidKamli[1], Firas AlTae[1], Omer F Kuzu[1] and **Arun Sikaruar[1]**
[1]Weill Cornell Medical College, Qatar
[2]Hamad General Hospital, Qatar

Hereditary Spastic Paraplegias (HSPs) are a group of rare neurological diseases of remarkable clinical and genetic heterogeneity. Cardinal features involve lower limbs spasticity, abnormal gait and difficult walking that eventually ends, in most of the cases, in being a wheel chair bound. Interestingly, presentation in patients with HSPs, particularly the autosomal recessive forms is much more than lower limbs spasticity and difficult walking. The variable association with developmental delay, psychomotor retardation, learning disabilities or even mental retardation, retinopathy, skin changes, distinctive brain malformation, ataxia, or extrapyramidal involvements brings up AR-HSPs as rare syndromes of broad clinical spectrum rather than just neurodegenerative spastic movement disorders. The axonal transport machinery, altered in HSP, comprises elaborate components of motor proteins, microtubules, shaping and distribution of subcellular organelles and enzymes involved in nucleotides or lipid metabolism. Families of different ethnic background; Qatari and other ethnicities, with a unified clinical feature of variably progressive lower limbs spasticity and walking difficulty were ascertained. Families either with only these standard features or in association with variable presentations of ataxia, pain insensitivity, remarkable vertebral destruction, regression in mental abilities, severe psychomotor retardation, and notable neuro-radiological abnormalities were enrolled in the study. Whole Genome Sequencing (WGS) was applied to identify candidate genes in the recruited families. Clinical findings are presented in addition to demographic and age groups' distribution, complex HSP rare phenotypes with interesting extraneural presentations, of which, features of marked pain insensitivity, skin changes and cerebellar atrophy were seen in independent families. WGS revealed involvements of rarely encountered HSPs genes, of which genes deriving purines and fatty acid metabolism and mitochondrial proteins. A family with double pathogenic mutations in Parkin gene and a known HSP gene was identified. Identification of causative genes of rare Mendelian diseases in a research sitting promotes the opportunity to diagnostics molecular genetics, improved genetic counseling qualities and primary prevention.

aka2005@qatar-med.cornell.edu

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Patients without diagnosis: A profile

Isabelle C Windheuser[1,2], Martin Muecke[1,2], Frank Klawonn[4] and **Christiane Stieber[1,2]**
[1]University Hospital Bonn, Germany
[2]University of Bonn, Germany
[3]Helmholtz Centre for Infection Research Biostatistics, Germany

A rare disease is defined as a disease that affects less than 1 in 2,000 people in Europe. In Germany, about 4 million individuals have a rare disease, which therefore represents a major public health issue, especially for the patients without a diagnosis. The demand for experts in rare diseases is correspondingly large, with insufficient points of contact for affected patients. To address this unmet need and improve the management of patients without diagnosis, the Center for Rare Diseases (ZSEB) at the University Hospital of Bonn founded a subunit, the "Interdisciplinary Competence Unit for Patients without Diagnosis" (InterPoD) in 2012. Since 2014, we have investigated the medical history of 242 patients with no established diagnosis and collected detailed information about their somatic, psychological and social aspects of health by using a standardized questionnaire. The aim of the study is to characterize the patients' collective data and retrospectively evaluating their data to create a patient profile. We determined the number and duration of medical assessments and investigations of patients without diagnosis before our evaluation through the InterPoD. We have also focused on determining the common accompanying symptoms or illnesses and have further investigated the most affected organ systems. Furthermore, we discuss how an unconfirmed diagnosis of a disease affects the patients' social wellbeing and daily life with regard to symptoms of depressive disorders and anxiety syndromes.

i.windheuser@uni-bonn.de

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Biochemical and electron microscopic changes induced by Giardia in experimentally infected lambs

Mervat E I Radwan
Benha University, Egypt

The present study was conducted to evaluate the effect of Giardia on the biochemical serum constituents of experimentally infected lambs, in addition to studying the observed alterations accompanying Giardia infection in the intestinal mucosa using scanning electron microscopy. Twenty lambs were allotted into two equal groups, Group A (infected) was orally inoculated by 104 Giardia cysts and Group B (non infected) was kept as control negative. The biochemical changes were assessed in both groups on 7th, 14th, 21th and 30th days post inoculation (dpi). The study disclosed that Giardia induced a significant drop in the levels of serum electrolytes (Cl, Na, K), blood glucose, different enzymes (lipase, amylase Alkaline phosphatase. Furthermore, the levels of urea, liver enzymes (alanine aminotransferase and aspartate aminotransferase), inflammatory marker (C-reactive protein) and oxidative stress markers malondialdehyde was elevated, but nitric oxide was declined from 21st day post infection till 30th day. The scanning electron microscopy of the intestinal mucosa of the infected lambs revealed a notable alteration which was fully explained. All the presented results interpret the pathophysiological effect of Giardia which adversely affects the health status of lambs.

Dr_mervat19@yaho.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Neglected tropical diseases: Road to control, elimination and eradication by 2020

Diego-Abelardo Alvarez Hernandez
Anahuac University, Mexico

Neglected Tropical Diseases (NTDs) are a diverse group of bacterial, parasitic and viral diseases that proliferate in tropical and subtropical environments through 149 countries. Currently, more than 1.4 billion people living in Africa, America and Asia are affected by at least 1 of the 17 NTDs recognized by the World Health Organization (WHO). NTDs are called neglected because they have been largely wiped out of the most developed areas, but they have persisted in the poorest and most marginalized societies, where inadequate sanitation due to the lack of clean water and poor hygiene, frequent contact with vectors and reservoirs and inadequate healthcare services prevail. If left untreated, NTDs may cause substantial illness and tremendous physical and emotional suffering, hampering children from attending to school and reducing adults economic productivity. As a result, families and communities become trapped in a cycle of disease and poverty. Fortunately, NTDs can be effectively managed if proper measures are implemented. While they have been around for centuries, the team effort to fight them is brand new. In 2011, the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases drew a roadmap for control, elimination and eradication for the 2012-2020 periods and in 2012, a community of partners endorsed the London Declaration on Neglected Tropical Diseases to commit themselves to enhance a better and accelerated response by working in alliance. As we consider both events as an historic set point to change the course of NTDs and as we find ourselves at half of the way of the planned period, it is time to analyze where do we stand on the roadmap and what areas of improvement should be reinforced. We still can achieve targets, but additional commitment is needed and each health professional should play its role to reach those left behind.

diego.alvarez.hernandez@hotmail.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Prevalence and outcome of Treatable lysosomal storage diseases in Children from north- eastern part of Libya

Professor Nuri M. Shembesh, Dr.abdulsallam A. Shakmak, DR.Fauzia Fazani, Dr.Amal Elwarfale and **Dr.Salma Elaubedee**
Department of pediatric and pediatric neurology, Benghazi children Hospital, Benghazi, Libya

Background: Lysosomal storage diseases are important inherited metabolic disorders with major healthcare concern. LSD occur at all ages and are clinically diverse, they differ greatly in their rate of progression and represent a large burden of illness in the population. The range of manifestations includes organomegaly, disturbed function of visceral organs, skeletal effects and neurological features. There is no specific or curative treatment for most lysosomal storage diseases, supportive and palliative treatment are nonetheless of great benefit .however recently recombinant DNA technology has led to the development of enzyme –replacement therapy for several lysosomal diseases. In this paper we present our experience from north-eastern part of Libya with some of this treatable LSD.

Methods: Twenty Seven cases with treatable LSD disorders were diagnosed and followed up in Benghazi children hospital during the period from (1997 – 2013) with Four different treatable LSD and general prevalence rate of 2.7/100.000. Initial work-up focused on clinical, laboratory and radiological evaluation. Lysosomal enzyme assay in peripheral blood leukocytes were performed according to standard techniques.

Results: Twelve children were diagnosed as Gaucher disease with prevalence rate of 1.2/100.000 The median age at diagnosis was 1 year, male to female ratio 1:1 , Six cases of Gaucher type one four of them on enzyme replacement two brother and sister with mild form on regular follow up without treatment . Four cases of type three all receiving cerozyme as replacement therapy and one child diagnosed as Gaucher type two died after one year of diagnosis he was also in Enzyme replacement therapy none of our patients has bone marrow transplant. Nine children were diagnosed as MPS1 with prevalence rate of 0.9/100.000 the median age at diagnosis was three years, male to female ratio 1.2:1, four have severe MPS1, three were moderate to severe form and one was mild form all of them received alldrozyme replacement therapy non had bone marrow transplant, of severe form one died and one lost follow up. Three brothers ,two of them were twin Diagnosed as MPS2 (Hunter) with low prevalence rate 0.3/100.000 all from Tobrok in the far east point of Libya ,non of them received enzyme replacement therapy till now . Three children were diagnosed as Pompe disease, with prevalence rate of 0.3/100,000. One patient was suspected as infantile pompe at one and half month of age died before result of enzyme assay. Two brothers diagnosed as juvenile pompe not on enzyme replacement therapy yet.

Conclusion: Lysosomal storage diseases, especially Gaucher and MPS1 disease, may represent important pathologies in our population and their prevalence rate was similar to the reported prevalence rate from other parts of the world .Specific diagnosis and follow-up is the key step in the accurate management and treatment of these patients.

nurishembesh@yahoo.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Consulting for a combination of molecular defects for variable expression

Yingjun Xie[1], **Haiming Yuan**[2, 3] and **Xiaofang Sun**[1]
[1]The Third Affiliated Hospital of Guangzhou Medical University, People's Republic of China
[2]Guangzhou KingMed Center for Clinical Laboratory Co., Ltd, China
[3]Guangzhou Medical University, China

Background: Expressivity is variable for most of the molecular defects. However, achondroplasia is a well-defined and common bone dysplasia, with an incidence of approximately 5-15 per 100,000 live births. Gain-of function mutations in FGFR3 have been shown to cause both chondrodysplasias and craniosynostoses and to result in impaired endochondral ossification.

Case Presentation: A 2-year-old boy with clinical features consistent with achondroplasia and Silver-Russell syndrome-like symptoms was studied. The patient exhibited features such as scoliosis and a trident configuration of the hands, all of which can be explained by a mutations in FGFR3 at c.1138 G >A (p.Gly380Arg). However, prenatal onset growth delay, the speech delay, hypotonia and small triangular face phenotypes were not commonly reported in previous cases of ACH. We further detected a three-fold increase in GRB10 expression. Combining with previous other studies, the one unique feature of this patient that can be directly linked to a GRB10 duplication is the prenatal onset growth delay.

Discussion: The data related to the patient described in the present study at least suggest that mutations in FGFR3 cause ACH, but do not influence the effects of the duplication of GRB10 on prenatal onset growth delay in SRS. The results of our study also suggest that phenotypes are rarely "simple" or directly related to specific gene defects and that combinations of uncommon, rare and exceptional molecular defects, which can be explored and used in diagnoses, may explain the so-called variability observed in the expression of dominant traits.

fairyfareyj@sina.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Rapid progression osteolysis in Gorham Stout Syndrome. A case report and literature review.

Iván Chérrez Ojeda MD, Leonardo Cano Cevallos MD and **Andrea Vélez Vera MD**
3Guangzhou Medical University, China

Background: Gorham-Stout Syndrome is a rare idiopathic nonmalignant disorder characterized by recurrent, progressive osteolysis. It may affect any bone, but commonly involves mandible, shoulder and pelvic girdle, each in roughly 20% of all the cases. The disease affects one or contiguous bones. Our purpose is to highlight the relevance of an extraordinary progression time in four months of massive osteolysis of the shoulder.

Case presentation: A 12-year-old-boy is admitted by complete loss of function of the right arm and showing a deformity at level of right clavicle. His history was characterized by progressive weakness and pain on right shoulder 4 months ago. . Biopsy results showed numerous congestive capillaries surrounded by fibrous tissue and blood material, also trabecular areas with irregular edges, perivascular inflammation and atrophy signs suggestive of angiomatosis confirmed the diagnosis of the disease

Conclusion: The time of progression of the disease in a normal pattern is at least one or two years within the beginning of suggestive symptoms. We consider that our case is particularly important because the progression to total destruction of elements of shoulder´s patient was four months in a young patient.

Keywords: Gorham Stout Syndrome, massive osteolysis, shoulder, rapid progression.

Dr_mervat19@yahoo.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

From promising molecules to orphan drugs: Early clinical drug development

Marc Dooms
Center for Clinical Pharmacology, Belgium

Phase-1 (also known as "First-in-Man") clinical trials initiate the early clinical development of possible new medicines. By raising the dose of the investigational compound in healthy volunteers pharmacokinetic and –dynamic parameters are recorded alongside the safety profile of the new substance in humans. Patient participation in this early phase of clinical trials will be rather limited. After successful phase -1 trials, further phase -2 and phase -3 clinical trials in patients may lead to a marketing authorization. In the first 15 years of the European Union Orphan Drug Directive 4-5- percent of the orphan drug applications were authorizated. However, for many of these orphan drugs no phase -1 studies were required as these products were already well known pharmaceutical substances with a clearly defined pharmacological profile. Furthermore, for 19 orphan drugs, already authorized by the European Medicines Agency, the original rare indication was extended to another rare disease and no phase -1 trials were needed. For all the other orphan drugs clinical development started with regular phase -1 studies in human volunteers.

dooms@evonet.be

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

The safety and efficacy of prednisolone in preventing re-accumulation of ascites among endomyocardial fibrosis patients in Uganda: A randomised clinical trial

Yvonne Brenda Nabunnya[1,2], James Kayima[1], Juergen Freers[1], Chris T Longenecker[2,3] and **Richard A Josephson[2,3]**
[1]Makerere University College of Health Sciences, Uganda
[2]Case Western Reserve University School of Medicine, USA
[3]UH Harrington Heart & Vascular Institute, USA

Background: Endomyocardial fibrosis (EMF), the commonest restrictive cardiomyopathy worldwide, is characterized by obliterative inflammation and fibrosis of the endocardium. Inflammation in other parts of the body such as the peritoneum may explain the accumulation of ascites, a painful and disabling feature of this disease. Therefore, we aimed to determine the efficacy and safety of prednisolone to prevent re-accumulation of ascites from International Ascites Club grade 2 to grade 3 among EMF patients attending Mulago Hospital's cardiology service.

Methods: This was a randomised placebo controlled trial with a 1:1 parallel design. Over a period of ten months, participants were recruited and randomized to receive 1 mg/kg per day of prednisolone or placebo and were followed for a maximum of 8 weeks. The primary outcome was re-accumulation of grade 3 ascites. Safety was assessed by self-reported side effects, physical exam and laboratory assessment.

Results: Sixteen patients were randomised to prednisolone, while 19 were randomised to placebo. Six patients were lost to follow up (1-prednisolone arm, 5-placebo). Baseline characteristics were balanced between groups, although only 4% had exudative ascites and only 10% had eosinophilia overall. Prednisolone was safely administered in this setting; however, there was no statistically significant difference in the overall risk of developing grade 3 ascites over 8 weeks (RR (95% confidence interval) 0.70 (0.439-1.114), p=0.12). The rate of the primary outcome per 1000 persons, after days of follow-up was also similar in both groups (p=0.63).

Conclusion: Short term prednisolone use was generally safe in this patient population; but there was no statistically significant evidence of efficacy. Additional studies are needed to assess the efficacy of anti-inflammatory treatments to slow progression of this disease.

yvonne.nabunnya@gmail.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Streptococcus suis: Bacteremia presenting with Fever, Rashes, Arthritis and Neurologic Deficits

Ahmad M. Domado
MD; Co-author: Jill Itable, MD, FPCP, DPSMID , Department of Internal Medicine, Southern Philippines Medical Center, Davao City, Ph 8000.

Streptococcus suis (S. suis) is a gram positive cocci acquired through exposure to infected swine. The most common clinical manifestation is meningitis often accompanied by bacteremia. *S. suis* is an emerging pathogen with significant complications, but remains to be underreported. Only 1,584 cases of *S. suis* infection have been reported worldwide with most of the cases concentrated in Southeast Asia where swine quantity is high. Despite a booming hog industry in the Philippines and increasing prevalence in its neighboring countries, *S. suis* infection remain unreported in our country due to either lack of available diagnostics or misdiagnoses. We report a case of a 52-year-old male who came in due to fever, generalized violaceous purpuric rash, headache, and nuchal rigidity. Patient was diagnosed with meningitis clinically. Patient consumed a diseased swine 5 days prior to admission. Blood culture was positive for Streptococcus suis II and clinical improvement was achieved with antibiotic treatment. Our patient is the second Filipino and the first documented case to be diagnosed in the Philippines. Patient is also the first documented case of a Filipino with Streptococcus bacteremia presenting with meningitis, hearing loss, skin lesions and arthritis. In *S. suis* infection, antibiotic treatment should be started without delay because a high mortality rate of up to 68% is observed in patients with septicemia and septic shock. With increased awareness and available diagnostics, a future outbreak, can be prevented.

ahmaddomado@yahoo.com, dmcimbet@yahoo.com
im@spmc.com.ph

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Development of orphan medical products

Martine Zimmermann
Alexion Pharmaceuticals, Inc., USA

Overview: This track will discusses opportunities and challenges associated with developing drugs for rare and ultra-rare diseases, and the use of novel approaches to bridge these challenges and successfully bring important lifesaving therapies to patients in need.

Context/Details: Between 5,000 and 8,000 districts, rare diseases exist; affecting around 27 million to 36 million people in the European Union. Collectively, these diseases represent a significant proportion of the population, and a growing healthcare concern since many of these rare disorders are serious conditions with no approved treatments. Since roughly 80% of these diseases have identified genetic origin, our scientific understanding of and ability to target these diseases is growing. Technological advances and our increased understanding of underlying disease biology has aided in the development of several groundbreaking therapies over the past ten years. In addition, heightened public policy support and push to find treatments for patients with rare and devastating diseases has helped in the adoption of legislative vehicles and regulatory programs that compliment scientific discovery and provide important development and financial incentives to companies to bring new targets from bench to bedside. Among them include expedited development and approval programs that offer enhanced regulatory dialogue and support for developers from early stages of clinical development through to approval. More and more we see appreciable regulatory support for innovative program design and increased regulator openness in applying regulatory flexibilities. All these factors have aided in the approval of important medicines for ultra-rare and devastating diseases. Yet challenges do persist in the development process; chief among them is the absence of knowledge about the disease itself, which is needed to inform important aspects of clinical development. Natural history for rare diseases is often poorly described or missing altogether given the small affected populations who themselves have variable phenotypes and clinical courses. For developers, it is important, early in the development process, to assess the depth and quality of this information so that a parallel study might better inform the development process. In this track, we will discuss the pathway to the development of rare diseases, starting with this most critical first step of assessing and acquiring knowledge of the disease itself through natural history studies. We will discuss endpoint selection, innovative design and leveraging expedited programs to help with small data sets. We will discuss ways in which frequent and early communication is essential. Finally, we will bring all these points together by using a real life example/case study.

martine.zimmermann@alexion.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Ion transport defects in Microvillus Inclusion Disease (MVID)

Nadia Ameen
Yale University School of Medicine, USA

Abstract: MVID is a rare congenital disease that results in severe secretory diarrhea (SD) and death in newborns. B rush border (BB) defects, villus atrophy and microvillus inclusions (MVIs) in enterocytes are associated with the diarrrhea. Loss of function mutations in the actin motor Myosin Vb (Myo5b) is responsible for most cases of MVID. How loss of Myo5b results in secretory diarrhea is unknown. The study used Myo5b loss of function human MVID intestine, polarized intestinal cell models of secretory crypt (T84) and villus resembling (C2BBe) enterocytes lacking Myo5b in conjunction with immunofluorescence confocal gSTED imaging, immunohistochemical staining, TEM, shRNA silencing, immunoblots, and electrophysiologic approaches to examine the distribution, expression and function of the major BB ion transporters (Na+ (NHE3), Cl- (CFTR) and Cl-/HCO3- (SLC26A3, DRA), that control intestinal fluid transport. NHE3 and DRA localization and function were markedly reduced on the BBM of human MVID enterocytes and Myo5bKD C2BBe cells, while CFTR localization was preserved. Forskolin-stimulated CFTR ion transport in Myo5bKD T84 cells resembled that of control.

Conclusions: Preservation of functional CFTR in immature enterocytes, reduced functional expression of NHE3 and DRA contribute to Cl- and Na+ stool loss in MVID diarrhea.

nadia.ameen@yale.edu

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Current challenges on Chagas disease

Jorge-Alberto Ascencio-Aragón
Universidad Anáhuac México Norte, Mexico

Chagas disease or American trypanosomiasis is recognized by the World Health Organization as one of the 18 neglected tropical diseases. It is estimated that there are between 7-8 million people infected, between 65-100 million people at risk of becoming infected and it causes nearly 12,000 deaths per year worldwide. Chagas disease is endemic of 21 Latin American countries, but the expanding migrational flows have made the disease an international health priority. It is a parasitic zoonosis caused by Trypanosoma cruzi, a protozoan with high genetic and phenotypic diversity that can be principally transmitted to human beings by the faeces of blood-sucking triatomines. Other mechanisms of transmission include; blood transfusions, organ or bone marrow transplants, from mother to child, by ingestion of food or drinks contaminated with triatomine faeces and due to occupational exposure. Chagas disease has a very broad-spectrum of clinical manifestations, depending upon the phase at where the patient is. Acute phase is characterized for passing unnoticed in 95% of the cases, unless Romaña's sign or chagoma develops at the inoculation site. Chronic phase is characterized for developing cardiac or gastrointestinal disease that lead to increased morbi-mortality. Diagnosis can be done with the combination of epidemiological background and clinical manifestations, if present, but laboratory tests are required for confirmation. Benznidazole and Nifurtimox are the only drugs available for treating the disease and meanwhile the efforts to formulate vaccines remain insufficient, patients suffer from a preventable disease whose main risk factor for acquiring it is living in poor and marginalised societies. Control of vector-borne transmission remains to be a challenge in endemic countries as it is related to low socioeconomic status, while serological screening at blood banks and monitoring of all pregnant women for non-vector-borne transmission can be effective to control the disease in non-endemic countries.

jorgeascarg@gmail.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Management of rare diseases: An integrated approach to break down barriers and facilitate patient access to healthcare

Gayathri Balasubramanian
Focus scientific research center (FSRC) at phamax, India

Background: In Europe, a rare disease is a disease that affects less than 1 in 2000. Although this seems to affect a fraction of the population, collectively it imposes a colossal. Rare diseases are disabling, dramatically reducing the quality of life, hampering routine activities and autonomous survival. Rare diseases management is intricate and varies across geographies. Understanding the complexities is important to resolve issues and improve care. Methodology: Secondary research of published and grey literature. Findings: Some of the challenges encountered in rare diseases management are delayed or misdiagnosis, lack of awareness on diseases/management, lack of quality healthcare at proximity, struggles to continued care, treatment access, and social consequences. In recent times, stakeholders such us healthcare providers, patient organizations, pharmaceutical companies, regulatory bodies and policy makers have taken many initiatives to resolve these challenges. National polices/plans are devised exclusively to manage rare diseases. Compassionate use programmes have encouraged research and provided accelerated entry of orphan drugs into the market. Organizations like EURORDIS have given voice to more than 300 rare disease organizations in over 30 countries. While these stakeholders, individually have endeavored to improve healthcare and social care, the complex challenges demands novel and integrative approach to effectively manage the rare diseases scenario (Figure). Additionally, leveraging on technology to create unified platforms and eHealth/mHealth programs can aid quick and better reach. Recommendation: Literature review has established some challenges and approaches to overcome them. However, in order to develop and implement an integrative approach in practice, the current drivers and barriers to effective management must be clearly explored. This demands a sequential explanatory research (quantitative study followed by qualitative) to explain quantitative results on current practices by exploring certain outcomes (especially unexpected ones) in depth. Eventually, an integrated approach can be developed to successfully address concerns and strengthen the management.

gayathri.balasubramanian@fs-researchcenter.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

45,X/46,X,i (X) (q10) isochromosome Xq in Mosaic Turner syndrome: A case report

Mark Ramon Victor B Llanes and **May Uyking-Naranjo**
Southern Philippines Medical Center, Philippines

Isochromosome Mosaic Turner Syndrome (IMTS) is a variant of Turner Syndrome (TS) characterized by cytogenetic profile of 1 or more additional cell lineages aside from 45,X, and the presence of a structurally abnormal X chromosome consisting of either two short or two long arms. IMTS is rare, with only 8-9% prevalence among women with TS based on international studies, and 15% of all TS in the Philippines. A 20 year old female came in due to amenorrhea and alopecia. Physical examination revealed short stature, cubitus valgus and Tanner Stage 1 pubic hair and breast development. Transrectal ultrasound revealed absent ovaries and infantile uterus. Hormonal evaluation revealed hypergonadotropic hypogonadism. Bone aging was that of a 13 year old for females with non fusion of epiphyseal plates. Cytogenetic study revealed 45,X [37]/46, X, i (X) (q10) [13]. This is consistent with a variant Isochromosome Mosaic Turner Syndrome. She was screened for medical complications. Audiogram and two-dimensional echocardiography were unremarkable. She has dyslipidemia and was given statins. She has subclinical hypothyroidism with positive test for anti-thyroglobulin antibody. Her intelligence quotient (IQ) was below average. She received conjugated estrogen and progesterone that patterned the hormonal changes in normal menstrual cycle. On the third week of hormonal therapy, she developed breast mound and on the fourth week, she had her first menstrual period. Her alopecia resolved spontaneously. The above case is a rare variant of Turner Syndrome requiring supportive, medical and psychological care.

markllanes22@gmail.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Sclerosing Angiomatoid Nodular Transformation of the Spleen: An Unusual finding in Paediatric Population

Godwin Oligbu[1,2], Indula Bopitiya[3], Praveen Saroey[1], Atra Ayad[4,5]
[1]Department of Paediatrics, St Georges Hospital London, UK
[2]Paediatric Infectious Disease Research Group, St Georges University of London, UK
[3]Department of Medicine, Imperial College, London, UK
[4]Department of Paediatric Haematology, St Georges Hospital, London, UK.
[5]Paediatric Oncology, Royal Marsden Hospital, London, UK

Background: Sclerosing angiomatoid nodular transformation (SANT) is a rare and benign primary vascular lesion of the spleen with unknown aetiology and pathogenesis its diagnosis is often incidental and is characterised by numerous angiomatoid nodules, in fibrous tissue, within the red pulp of the spleen. The neoplasm has shown a predilection for adult females with cases in the paediatric population being exceptionally rare.

Case summary: We present an asymptomatic 14-year-old boy with incidental examination findings of scanty bruising and massive splenomegaly. Blood tests revealed pancytopenia with normal coagulation studies, raised C-reactive protein however normal erythrocyte sedimentation rate. Abdominal CT and ultrasound scans showed increasing splenomegaly (the largest size being 27cm) with one discrete focal lesion, small perihilar splenic lymph nodes and an enlarged splenic vein (Figure 1). The patient underwent splenectomy for diagnostic and therapeutic purposes with good long-term outcome and normalisation of the full blood count. Subsequent histological analysis revealed a prominent, nodular, 15mm mass with slit-like or irregular shaped vascular spaces that was typical of SANT. Immunohistochemistry was positive for CD8, CD31 and CD34, which was in keeping with results found in previous cases. We also found D240 to be positive. The boy was also diagnosed with congenital retinoschisis and Scheuermann's disease of the spine.

Conclusions & Significance: We identify common features, in the presentation, diagnosis and management of this rare condition in paediatrics, as well as documenting our own unique findings including normal erythrocyte sedimentation rate and D240 immunotyping. Although uncommon, SANT should be included in the differential diagnosis of children presenting with splenomegaly and a well circumscribed, hypovascular lesion on CT imaging. Long term follow up of this cohort of adult and paediatric patients is required to better understand the epidemiology of this condition.

godwin.oligbu@nhs.net

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Drug repurposing screen for rapid identification of therapeutics for Zika virus infection

Wei Zheng
Ph.D., National Center for Advancing Translational Sciences, National Institutes of Health, USA

Zika virus infection with complications of microcephaly and other complications has emerged as a health threat in many countries the infection has been reported over 60 countries. Vaccines and therapeutics are currently unavailable for the Zika virus infection. We have developed several compound screening assays and carried out the drug repurposing screens to identify potential therapeutics for the Zika virus infection. The newest results on drug repurposing screens and Zika virus drug development will be presented in this talk.

wei.zheng@nih.gov

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

Retrodifferentiation in the treatment of a rare condition: Acquired aplastic anaemia

Ilham Abuljadayel
TriStem Corp Ltd, UK

Stem cells can offer cures to treat many rare diseases, which can be used to correct a plethora of genetic conditions or replenish damaged tissue and cells in acquired disorders, in allogeneic or autologous manners, respectively. The limiting factors for such applications are; the availability and quantity of the stem cell source, the identification of a suitable histocompatible donor and the aggressive nature of ablation therapies that enable engraftment. On the other hand, retrodifferentiation technology which is similar to epimorphic regeneration, albeit, occurs ex vivo, offers a rapid additional source of stem cells with high efficiency. The process involves dedifferentiation/retrodifferentiation of mature adult cells such as peripheral leukocytes into a heterogeneous population of stem cells belonging to a give tissue. Retrodifferentiation procedure produces unlimited supply of stem cells from patient or donor blood which have been shown to be safe as well as capable of long term engraftment. Furthermore, the autologous retrodifferentiated stem cells have been shown to engraft human bone marrow in the absence of ablation, in a rare disease such as acquired aplastic anaemia. This presentation will focus on the production of multipotent stem cells prepared from mononuclear cells and its application in the treatment of aplastic anaemia, a rare condition if left untreated lead to rapid morbidity.

iabuljadayel@tristemcorp.com

Notes:

J Genet Syndr Gene Ther 2018, Volume 9
DOI: 10.4172/2157-7412-C1-019

45,X / 46,X,i (X) (q10) Isochromosome Xq in mosaic turner syndrome: A case report

Mark Ramon Victor B. Llanes, MD, May Uyking-Naranjo
Southern Philippines Medical Center

Isochromosome Mosaic Turner Syndrome (IMTS) is a variant of Turner Syndrome (TS) characterized by cytogenetic profile of 1 or more additional cell lineages aside from 45,X, and the presence of a structurally abnormal X chromosome consisting of either two short or two long arms. IMTS is rare, with only 8-9% prevalence among women with TS based on international studies, and 15% of all TS in the Philippines. A 20 year old female came in due to amenorrhea and alopecia. Physical examination revealed short stature, cubitus valgus and Tanner Stage 1 pubic hair and breast development. Transrectal ultrasound revealed absent ovaries and infantile uterus. Hormonal evaluation revealed hypergonadotropic hypogonadism. Bone aging was that of a 13 year old for females with non fusion of epiphyseal plates. Cytogenetic study revealed 45,X [37]/46, X, i (X) (q10) [13]. This is consistent with a variant Isochromosome Mosaic Turner Syndrome. She was screened for medical complications. Audiogram and two-dimensional echocardiography were unremarkable. She has dyslipidemia and was given statins. She has subclinical hypothyroidism with positive test for anti-thyroglobulin antibody. Her intelligence quotient (IQ) was below average. She received conjugated estrogen and progesterone that patterned the hormonal changes in normal menstrual cycle. On the third week of hormonal therapy, she developed breast mound and on the fourth week, she had her first menstrual period. Her alopecia resolved spontaneously. The above case is a rare variant of Turner Syndrome requiring supportive, medical and psychological care.

markllanes22@gmail.com

Notes:

INDEX

Abdulaziz Aldawood	38
Duaa Mohammadat	54
Gianluca Colella	37
Gianluca Colella	45
Gilstrap A	42
Laxminarayan Bhat	36
Laxminarayan Bhat	43
Mady Ndiaye	52
Samuel Ayoola Abati	50
Tatjana Michel	44
Tatjana Michel	51
Williams KR	49
Yolande van Bever	41
Yuqing shi	55

Meet Inspiring Speakers and Experts at our 3000+ Global Events with 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology, Business and 700+ Open Access Journals

Conferences | Publishing | Global Networking | Research | Business

Exhibitions | Collaborations | Careers | International Memberships | Advertisements & Promotions

Conferences By Continent

USA & Americas

USA | Brazil | Canada | Mexico

Asia-Pacific

Australia | China | India | Japan | Malaysia | New Zealand | Philippines | Singapore | South Korea

Europe & Middle East

Austria | Denmark | Finland | France | Germany | Italy | Netherlands | Norway | Poland | South Africa | Spain | Switzerland | Turkey | UAE | UK | Ukraine

Medical & Clinical Journals and Conferences

- Alternative Healthcare
- Cardiology
- Dentistry
- Dermatology
- Diabetes & Endocrinology
- Gastroenterology
- Healthcare Management
- Hematology
- Infectious Diseases
- Medical Ethics
- Health Policies
- Neuroscience
- Nephrology
- Nursing
- Obesity
- Oncology & Cancer
- Ophthalmology
- Palliativecare
- Pathology
- Pediatrics
- Physical Therapy Rehabilitation
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Vaccines
- Reproductive Medicine &
- Women Healthcare

Journals and Conferences by Subject

- Agri, Food & Aqua
- Biochemistry
- Business & Management
- Chemical Engineering
- Chemistry
- EEE & Engineering
- Environmental Science
- Genetics & Molecular Biology
- Geology & Earth Science
- Immunology
- Materials Science
- Microbiology
- Nanotechnology
- Nutrition
- Oncology & Cancer
- Petroleum
- Pharma Marketing & Industry
- Pharmaceutical Sciences
- Physics
- Veterinary

Contact us

Conference Series llc LTD - UK
47 Churchfield Road, London, W3 6AY
Toll Free: +1-800-014-8923
E: europe@conferenceseries.com

Conference Series - Asia Pacific
6th Floor, North Block, Divyasree Building, Raidurg, Hyderabad
Telangana, INDIA-500032 P: +91-40-33432300
E: asia@conferenceseries.com

Toll Free

Australia - 1-800-651-097 | **France** - 0805-080048 | **Hyderabad** - 91-40-71279012

Hyderabad - 91-40-71279013 | **UK** - 0-800-014-8923

Los Angeles Downtown - 1-213-233-9462 | **USA/Canada** - 1-888-843-8169

CME CREDITS

Physicians, Health professionals including Nurses and Nurse practitioners, Physician assistants, Psychologists, Social workers, Family therapists, Dieticians and Pharmacists

10th International Virology Summit
July 02-04, 2018 Vienna, Austria
E: eurovirology@microbiologyconferences.org
W: virology.conferenceseries.com/europe

6th International Congress on
Gynecology & Gynecologic Oncology
July 23-24, 2018 Rome, Italy
E: gynecology@nursingmeetings.com
W: gynecologiccancer.conferenceseries.com

6th World Congress on
Control and Prevention of HIV/AIDS, STDs & STIs
August 27-28, 2018 Zurich, Switzerland
E: std@infectiousconferences.com
W: globalhiv-aids-std.infectiousconferences.com

20th International Conference on
Pediatrics & Primary Care
September 03-04, 2018 Zurich, Switzerland
E: pediatricprimarycare@annualconferences.org
graciejones033@gmail.com
W: primarycare.pediatricsconferences.com

29th International Conference on
Adolescent Medicine & Child Psychology
September 04-06, 2018 Zurich, Switzerland
E: childpsychology@psychiatrycongress.com
W: childpsychology.conferenceseries.com

4th International Conference on
Hypertension & Healthcare
September 10-11, 2018 Zurich, Switzerland
E: hypertensionconference2018@rediffmail.com
W: hypertension.conferenceseries.com

24th European Pediatrics Conference
September 10-11, 2018 Copenhagen, Denmark
E: europediatrics@gmail.com
europediatrics@annualconferences.org
W: pediatrics.conferenceseries.com/europe

11th Annual Congress on
Immunology & Immunotechnology
September 13-14, 2018 Zurich, Switzerland
E: immunologycongress@annualconferences.org
W: immunologycongress.immunologyconferences.org

24th World Nursing and Healthcare Conference
September 13-15, 2018 Copenhagen, Denmark
E: worldnursing@nursingconference.com
W: world.nursingconference.com

6th International Conference on
Brain Disorders and Therapeutics
September 13-15, 2018 Copenhagen, Denmark
E: braindisorder@neuroconferences.com
W: braindisorders.conferenceseries.com

7th International Conference on
Neurological Disorders & Stroke
September 20-21, 2018 Rome, Italy
E: stroke@annualconferences.org
W: stroke.neurologyconference.com

29th International Congress on
Prevention of Diabetes and Complications
September 27-28, 2018 Berlin, Germany
E: diabetesmeeting@endocrineconferences.com
W: diabetesmeeting.conferenceseries.com

13th World Conference on
Neurology and Neuromuscular Disorders
October 01-02, 2018 Frankfurt, Germany
E: neuromuscular@surgerymeetings.com
W: neuromuscular.neuroconferences.com

17th International Conference on
Clinical and Experimental Ophthalmology
October 01-03, 2018 Moscow, Russia
E: ophthalmology@ophthalmologyconferences.com
W: ophthalmology.conferenceseries.com

5th International Conference on
Gynecology and Obstetrics
October 08-10, 2018 Zurich, Switzerland
E: gynecology@nursingconference.com
W: gynecology.conferenceseries.com

3rd European Otolaryngology-ENT Surgery Conference
October 08-10, 2018 London, UK
E: entsurgery@surgeryconferences.org
W: ent.conferenceseries.com

conferenceseries.com

CME CREDITS

Physicians, Health professionals including Nurses and Nurse practitioners, Physician assistants, Psychologists, Social workers, Family therapists, Dieticians and Pharmacists

33rd Euro Nursing & Medicare Summit
October 08-10, 2018 Edinburgh, Scotland
E: euronursing@nursingconference.com
W: europe.nursingconference.com

36th World Cancer Conference
October 11-13, 2018 Zurich, Switzerland
E: worldcancer@meettheglobalexpert.com
W: cancer.global-summit.com

25th World Pediatrics Conference
October 18-20, 2018 Warsaw, Poland
E: worldpediatricsconference@gmail.com
W: worldpediatrics.pediatricsconferences.org

7th International Chronic Obstructive Pulmonary Disease Conference
October 22-23, 2018 Rome, Italy
E: copdconference@meettheglobalexpert.com
W: copd.conferenceseries.com/europe

27th European Cardiology Conference
October 22-24, 2018 Rome, Italy
E: eurocardiology@cardiologymeeting.com
W: cardiologyconference.cardiologymeeting.com

12th International Conference on
Alzheimer's Disease & Dementia
October 29-31, 2018 Valencia, Spain
E: dementia@neuroconferences.org
W: alzheimers-dementia.neuroconferences.com

35th International Conference on
Psychiatry & Psychosomatic Medicine
November 01-03, 2018 Brussels, Belgium
E: psychosomaticmedicine@psychiatrycongress.com
W: psychosomatic.conferenceseries.com

4th International Conference on
Central Nervous System Disorders & Therapeutics
November 12-14, 2018 Edinburgh, Scotland
E: cns@neuroconferences.com
W: cns.conferenceseries.com

9th Global Experts Meeting on
Neuropharmacology
November 15-16, 2018 Frankfurt, Germany
E: neuropharmacology@conferenceseries.net
W: neuro.pharmaceuticalconferences.com

29th World Cardiology Conference
November 19-20, 2018 Edinburgh, Scotland
E: worldcardiology@cardiologymeeting.com
W: worldcardiology.conferenceseries.com

22nd European Nutritional Science Congress
November 26-27, 2018 Barcelona, Spain
E: nutritionalscience@annualconferences.org
W: nutritionalscience.nutritionalconference.com

27th European Ophthalmology Congress
November 26-28, 2018 Dublin, Ireland
E: ophthalmologycongress@ophthalmologyconferences.com
W: ophthalmologycongress.ophthalmologyconferences.com

Upcoming Rare Diseases & Orphan Drugs Conferences

4th International Conference on
Influenza and Zoonotic Diseases
July 2-3, 2018, Vienna, Austria
W: influenza.conferenceseries.com

9th International Conference on
Emerging Infectious Diseases
August 27-28, 2018 Zurich, Switzerland
W: emerging-diseases.infectiousconferences.com

6th World Congress on
Control and Prevention of HIV/AIDS, STDs & STIs
August 27-28, 2018 Zurich, Switzerland
W: globalhiv-aids-std.infectiousconferences.com

10th Euro-Global Conference on
Infectious Diseases
September 27-29, 2018 Rome, Italy
W: infection.conferenceseries.com/europe

14th World Congress on
Infection Prevention and Control
December 6-7, 2018 Valencia, Spain
W: infectionprevention.insightconferences.com

6th International Congress on
Infectious Disease s
Feb 25-26, 2019 London, United Kingdom
W: infectioncongress.conferenceseries.com

Bookmark your dates

9th World Congress on

Rare Diseases and Orphan Drugs

June 17-18, 2018 Rome, Italy

E-mail: rarediseasecongress@infectiousconferences.com
Website: https://rarediseases.conferenceseries.com/europe/